Men’s beliefs about treatment for erectile dysfunction – What influences treatment use? A systematic Review by Williams, P. et al.
              
City, University of London Institutional Repository
Citation: Williams, P., McBain, H. B. ORCID: 0000-0002-6742-1104, Amirova, A., 
Newman, S. P. ORCID: 0000-0001-6712-6079 and Mulligan, K. ORCID: 0000-0002-6003-
3029 (2020). Men’s beliefs about treatment for erectile dysfunction – What influences 
treatment use? A systematic Review. International Journal of Impotence Research, doi: 
10.1038/s41443-020-0249-1 
This is the accepted version of the paper. 
This version of the publication may differ from the final published 
version. 
Permanent repository link:  https://openaccess.city.ac.uk/id/eprint/23740/
Link to published version: http://dx.doi.org/10.1038/s41443-020-0249-1
Copyright and reuse: City Research Online aims to make research 
outputs of City, University of London available to a wider audience. 
Copyright and Moral Rights remain with the author(s) and/or copyright 
holders. URLs from City Research Online may be freely distributed and 
linked to.
City Research Online:            http://openaccess.city.ac.uk/            publications@city.ac.uk
City Research Online
1 
Men’s beliefs about treatment for erectile dysfunction – What 1 
influences treatment use? A systematic Review  2 
 3 
Running title: Systematic review: erectile dysfunction treatment.  4 
 5 
Paul Williams MSc1, Hayley McBain PhD CPsychol1, Aliya Amirova MSc1, Stanton Newman B Soc Sci, 6 
DPhil, DipClinPsy DPhil1 Kathleen Mulligan PhD CPsychol1 2* 7 
 8 
1 Centre for Health Services Research, School of Health Sciences, City, University of London, UK.           9 
2 Community Health Newham, East London NHS Foundation Trust, UK.  10 
*Corresponding author: 11 
Dr Kathleen Mulligan 12 
E: Kathleen.mulligan.1@city.ac.uk 13 
 14 
2 
1. Abstract  15 
Successful treatment of erectile dysfunction (ED) is associated with improvements in quality of life; 16 
however, treatment utilisation is sub-optimal. The aim of this systematic review was to identify the 17 
rates of ED treatment utilisation and the barriers and enablers men experience when using 18 
treatment.  19 
We searched: MEDLINE®, Embase, the Cochrane library; AMED; HMIC; HTA; CINAHL; PsychARTICLES; 20 
PsychINFO up to August 2018. Data on rates of treatment utilisation and barriers and enablers of 21 
utilisation were extracted and summarised.  22 
Fifty studies were included. Discontinuation rates ranged from 4.4-76% for phosphodiesterase type 5 23 
inhibitors, 18.6-79.9% for intracavernosal injections, 32-69.2% for urethral suppositories. In relation 24 
to those with a penile prosthesis; 30% discontinued having sex due to e.g. device complications, lack 25 
of partner or a loss of sexual interest. 26 
Most research included in the current review examined barriers to treatment utilisation and 27 
therefore focussed on reasons for discontinuing treatment. However, a small number explored 28 
factors that men found helpful with regards to treatment utilisation. The most prevalent barriers to 29 
utilisation were treatment ineffectiveness, side-effects, the quality of men’s intimate relationships 30 
and treatment costs. With regards to treatment enablers, the most salient finding was that men who 31 
reported side-effects to a health care profesionals (HCPs) were significantly less likely to discontinue 32 
treatment. There were limitations in methodology in that the studies did not use validated measures 33 
of treatment utilisation or barriers and enablers and no study used psychological theory to inform 34 
the examination of factors that influenced treatment utilisation.   35 
This review identifies a number of influential factors relating to ED treatment utilisation and 36 
highlights the importance of men’s beliefs with regards to ED and its treatment. Beliefs are 37 
potentially modifiable and therefore the findings of this review highlight important considerations 38 
for health care professionals with regards to supporting men to make better use of treatment.  39 
3 
2. Introduction 40 
Erectile dysfunction (ED) is defined as the persistent inability to attain and/or maintain a penile 41 
erection adequate for sexual performance (1). Prevalence increases with age affecting 42 
approximately 1–10% of men up to the age of 40 years, 2-9% of men aged between 40 and 49 years, 43 
increasing to 20–40% in those aged 60–69 years and 50-100% in those over 70 (2). ED can have a 44 
negative impact on self-confidence, mood and quality of life (3-9). Improvements in psychological 45 
status, self-esteem and perceived relationship quality can be achieved by improving sexual function 46 
through the use of treatment (10-15). 47 
Phosphodiesterase type 5 inhibitors (PDE5Is) are the first line treatment for ED (16). Where PDE5Is 48 
are ineffective or contraindicated, alternatives such as intracavernous injections (ICI), urethral 49 
suppositories (US), vacuum erection devices (VEDs) and penile prosthesis (PP) remain available (17). 50 
PDE5Is are considered safe, effective and tolerable for men with ED (18). Despite this, adherence to 51 
PDE5Is has been described as sub-optimal due to factors such as, side-effects, not wanting a sexual 52 
schedule dependent on a medication regimen, the delayed response between taking the medication 53 
and its effect as well as the financial cost of treatment (19). Psychosocial explanations include 54 
performance anxiety, depression, varying arousal patterns and misaligned expectations between a 55 
man and his partner (20). 56 
To date there has not been a synthesis of research investigating adherence to ED treatment. 57 
National guidelines for medication adherence (21) recognise that in order for health care 58 
professionals (HCPs) to support patients, a better understanding of factors that influence patients’ 59 
decisions regarding treatment utilisation is necessary. Therefore, the aim of this systematic review 60 
was to identify barriers and enablers to ED treatment utilisation and the extent to which they 61 
influence men’s decisions to utilise their treatment. The review will serve as a foundation to develop 62 
future interventions to facilitate ED treatment utilisation.   63 
4 
3. Material/Subjects and Methods 64 
The protocol was registered on PROSPERO (reference CRD42015023341).  65 
3.1 Search strategy  66 
MEDLINE®, Embase, Cochrane Central Register of Controlled Trials,  Health Management 67 
Information Consortium (HMIC), Health Technology Assessment, CINAHL plus with full text, 68 
PsychARTICLES, PsychINFO and Allied and Complementary Medicine (AMED) were searched from 69 
inception to August 2018 . English language key words and MeSH terms for ED, adherence and 70 
treatment for ED, were used and combined using Boolean logical operators (see Supplementary 71 
Information). 72 
3.2 Inclusion Criteria 73 
Studies had to meet the following criteria:  74 
• Published in a peer reviewed journal in English  75 
• Primary research of qualitative, quantitative or mixed methodologies  76 
• Include an assessment of treatment utilisation  77 
• Include an assessment of patient barriers and/or enablers to ED treatment utilisation  78 
• Include participants who were  79 
o Men aged ≥18 years  80 
o Diagnosed with ED either using a validated diagnostic tool or by a relevant HCP i.e. a 81 
GP or urologist  82 
o Prescribed PDE5Is, ICI, US, VEDs or PP.  83 
3.3 Exclusion Criteria  84 
Systematic reviews, conference proceedings, commentary articles and letters were excluded. 85 
3.4 Study Selection and Data Extraction 86 
Articles were imported into Thomson Reuters Reference Manager v12.0 and duplicate records 87 
removed. Two authors (PW, AA) independently screened titles and abstracts to exclude ineligible 88 
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studies, followed by full-text screening of the remainder. Any disagreements were discussed with a 89 
third author (HM) to reach consensus. Data were extracted using an adapted Cochrane Data 90 
Extraction Form (22). 91 
3.5 Quality Assessment 92 
The QualSyst tool was employed to assess study quality due to its ability to cater for both qualitative 93 
and quantitative designs (23). Final scores were converted into a percentage where <50% indicates 94 
limited quality, 50–70%: adequate; 71–80%: good, and >80%: strong (24). Scoring was carried out by 95 
one author (PW) and checked by a second (AA). 96 
3.6 Synthesis 97 
A narrative synthesis, considered the most appropriate method of synthesising qualitative and 98 
quantitative evidence (25), was conducted. Barriers and enablers of treatment utilisation were 99 
classified into one of six categories: 100 
o Demographic; age, gender, ethnicity, education.  101 
o Clinical; nature of the condition and treatment; including side-effects and medication efficacy. 102 
o Psychological and cognitive:  individual-level processes and meanings that influence mental 103 
states such as depression, stress and beliefs about ED or its treatment. 104 
o Social: social processes that impinge on the individual, such as relationship quality. 105 
o Behavioural: observable behaviours (as opposed to internal events such as thinking), which 106 
can be objectively measured, such as the length of time before seeking help for ED. 107 
Depending on the study, the percentage of overall participant’s discontinuation, persistence or 108 
adherence was reported. Studies indicating the same barriers and enablers to treatment were 109 
grouped together and the number/percentage of participants reporting a particular 110 
barriers/enablers as being influential were reported (see supplementary material).     111 
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3.4 Terminology  112 
The use of the term ‘adherence’ is synonymous with overlapping definitions, such as compliance and 113 
persistence. Studies of medication usage lack uniformity in definitions (26), therefore, due to the 114 
neutrality of its meaning, the current review will use the term ‘treatment utilisation’ to describe 115 
usage patterns.  116 
4. Results 117 
4.1 Literature search 118 
A total of 3,232 papers were retrieved, 129 underwent full text screening and 50 studies were 119 
included (See Figure 1). 120 
4.2 Study Characteristics 121 
All studies used a quantitative study design (Table 1), except one that employed a mixed 122 
methodology. The qualitative component of this study was reported as frequency data and was 123 
therefore interpreted quantitatively (27). Study designs included retrospective (n=5) and prospective 124 
cohort designs (n=29), cross-sectional studies (n=8), randomised trials (n=5), a randomised control 125 
trial (n=1), quasi experimental study (n=1) as well as mixed-methodology (n=1). Almost one third of 126 
studies were conducted in the USA (n=15). Although all studies examined barriers/enablers to 127 
treatment utilisation, this was the primary focus for only 24 studies. Other studies’ primary focus 128 
was ED treatment-related factors such as acceptability, safety, efficacy, satisfaction and tolerability 129 
(n=25) and one study focussed on help seeking behaviour (n=1).  130 
Thirty-three studies (66%) focussed on PDE5I medication, twelve (24%) on ICI therapy, three (6%) on 131 
US and two (4%) on multiple treatments, of which one included PP. Studies were conducted 132 
between 1991 and 2017.  133 
4.3 Participant characteristics 134 
Data related to 14,371 men. Mean age, reported in 46 studies, ranged from 39.9-69.1 years. Five 135 
studies reported ethnicity (28-32), where 67.2-97.8% were classified as white/Caucasian. Seven 136 
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studies reported on relationship status (27, 29, 33-37), where 61.5–96.0% were described as having 137 
a partner (Table 2).  138 
4.4 Clinical characteristics 139 
Twenty-three studies (46.0%) used the International Index of Erectile Dysfunction (IIEF) (38) or the 140 
Sexual Health Inventory for Men (SHIM) (39) to assess ED severity, moderate ED was most prevalent 141 
(33.3-61.7%). ED duration, reported in 21 studies, ranged from 3-72 months. Twenty studies 142 
provided data on ED aetiology, 6.3-86% were classified as having organic ED, 5.0-36.3% psychogenic, 143 
and 15-71% as having mixed ED. Twenty studies reported on comorbidities; hypertension (5.0-144 
51.9%) and diabetes (4.4-42.4%) were most commonly reported. Eight studies recruited exclusively 145 
men who had undergone a prostatectomy. 146 
4.5 Study quality  147 
Quality scores ranged from 41-100%, 7 (14%) were classified as limited, 22 (44%) as adequate, 4 (8%) 148 
as good and 17 (34%) as strong. Lower scores typically related to limited or no provision of 149 
definitions of outcome measure/s, neglecting information on power calculations, sample or effect 150 
sizes and not controlling for confounding variables. 151 
4.6 Definitions of Treatment Utilisation 152 
There were a variety of different definitions of treatment utilisation and discontinuation (Table 3). 153 
Due to the heterogeneity of definitions, synthesis was achieved through a top-down application of 154 
the following definitions; 155 
- Adherence: conforming to recommendations made by the HCP with respect to timing, dosage, 156 
and frequency of medication utilisation.  157 
- Persistence: continuing to take any amount of medication (26). 158 
- Discontinuation: cessation of treatment.   159 
Forty-four studies were classified as measuring discontinuation, three; persistence and three both 160 
adherence and persistence.   161 
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4.7 Measures of Treatment Utilisation 162 
Thirty-four studies (68%) used self-report measures to investigate treatment utilisation including; 163 
questionnaires, patient diaries, consultations and telephone surveys (Table 3). Other methods 164 
included for example prescription records (n=2) and twelve studies did not report their method. No 165 
validated measures of treatment utilisation were used.  166 
4.8 Rates of Treatment Utilisation 167 
Rates of adherence to PDE5Is ranged from 59.6-70.2%, persistence from 64.9-100% and 168 
discontinuation from 4.4-76%. Follow-up periods varied from 3-48 months. ICI discontinuation rates 169 
ranged from 18.6-79.9%, in which follow-up ranged from 3-65 months. Discontinuation of US ranged 170 
from 32-69.2%, in which follow-up ranged from 9–27 months. The one study that explored PP, 171 
followed men over a 65 month period where 30% stopped having sex due to complications with the 172 
device itself or due to periphery reasons such as a lacking a partner or a loss of sexual interest (40).  173 
It might be expected that longer follow-up periods infer higher rates of discontinuation or poorer 174 
adherence; no such pattern emerged. Similarly, there was no pattern of association between rates 175 
of treatment utilisation and sample size, study design, or country in which the study took place 176 
(Table 3). 177 
4.9 Barriers and enablers of treatment utilisation 178 
Thirty-seven studies (74%) used self-report measures to investigate barriers and enablers to 179 
treatment utilisation, mostly self-report questionnaires (Table 3). Other methods included clinical 180 
and demographic data (n=2) as well as prescription renewals (n=1). However, ten studies did not 181 
clarify their method. Less than half of included studies (n=18) examined whether there was a 182 
statistically significant relationship between potential barriers or enablers and treatment utilisation. 183 
The remaining 32 studies reported descriptive statistics only. For each barrier or enabler, descriptive 184 
data from relevant studies was combined and presented as a total percentage of participants across 185 
relevant studies. None of the studies used a validated measure or a theoretical approach to 186 
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investigate barriers and enablers to treatment utilisation. Based on the studies included, the 187 
following sections will consider the most widely reported barriers and enablers to ED treatment 188 
utilisation. 189 
4.10 Demographic Factors  190 
Sixteen studies (32%) examined the relationship between demographic factors and use of PDE5Is 191 
(n=12) or ICI treatment (n=4) (see Table 4).  192 
Age 193 
Twelve studies examined the relationship between age and PDE5I utilisation (29, 34-37, 41-47). One 194 
reported older age as a barrier, however, this was based on descriptive statistics (43). Eleven 195 
performed statistical analysis, for which findings were inconsistent. Three studies reported 196 
significantly higher rates of discontinuation for men over 60 years (31, 36, 44); however, older men 197 
were reported as being significantly more persistent and adherent according to two other studies 198 
(35, 42). Six studies reported a non-significant relationship (34, 37, 41, 45-47); as did studies focused 199 
on ICI treatment (48-50). 200 
Education 201 
Five studies investigated levels of education and PDE5I utilisation using inferential statistics (34, 37, 202 
41-43). Results were conflicting. One study indicated that higher levels of education related to 203 
significantly higher rates of utilisation (34). However, after controlling for age, delay in seeking 204 
medical help, relationship status and SHIM score; one study reported the relationship to be non-205 
significant (37). A further study reported a higher level of education relating to significantly higher 206 
rates of persistence but not adherence (43) and finally, two studies reported a non-significant 207 






Employment  213 
Three studies explored the effects of employment on PDE5I utilisation (29, 41, 42). Full-time 214 
employment related to significantly higher rates of persistent (42) and adherence (41, 42) compared 215 
to being part-time, retired or unemployed. One study, however, reported the relationship to be non-216 
significant (29).      217 
Clinical factors 218 
All fifty studies examined the relationship between one or more clinical factors and treatment 219 
utilisation (Table 4).  220 
Treatment Ineffectiveness  221 
Ineffectiveness of PDE5Is was explored by twenty-two studies (27-32, 35, 36, 43, 45, 46, 51-61), 222 
eleven on ICI treatment (40, 49, 61-69), four on US (61, 70-72) and one on PP (40).    223 
PDE5I ineffectiveness related to hardness and duration of erection. Across all studies 12.1% (range: 224 
0.2-60%) of participants reported ineffectiveness as a reason for discontinuation.  225 
Ineffectiveness of ICIs related to inadequate erectile response and was explored using descriptive 226 
statistics by ten studies, where 15.2% (range: 5–39.3%) discontinued for such reasons. One study 227 
used inferential statistics and reported significantly higher rates of discontinuation where treatment 228 
was ineffective (49).    229 
Ineffectiveness of US was characterised by insufficient erections as well as a lack of a consistent 230 
reliable response (70-72); 31.5% (range: 16-50.8%) of participants across studies discontinued for 231 
this reason. Finally, 4.7% of participants reported prosthesis malfunction as a reason for 232 
discontinuation (40). 233 
Perceived side-effects 234 
The experience of side-effects was reported in twenty-one studies focussed on PDE5Is (27, 29-32, 235 
34-36, 45, 46, 51, 52, 54, 55, 59-61, 73-76), twelve on ICI (40, 48, 49, 61, 62, 64-69, 77), three on US 236 
(61, 71, 72) and one on PP (40).   237 
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Across 21 studies, 2.5% (range: 0.9-16%) of men discontinued PDE5Is due to side-effects, which 238 
included headaches, rhinitis, Peyronie’s disease and chest pain. Three of these studies used 239 
statistical analysis, one of which found side-effects to be related to significantly higher rates of 240 
persistence (45). Similarly, where men reported side-effects to a HCP they were significantly less 241 
likely to discontinue treatment (35). However, one study reported the relationship to be non-242 
significant (31).  243 
ICI treatment side-effects included injection pain, priapism, Peyronie’s disease and fibrosis of the 244 
penile shaft. Across twelve studies, side-effects were reported by 8.1% (range: 0.9-20.9%) of men as 245 
the reason for discontinuation. According to one study, side-effects related to significantly higher 246 
rates of discontinuation (49), however, a further study found no such relationship (48). 247 
Side-effects of US included urethral pain and burning, where 15% (range: 7.4–32%) of men across 248 
studies reported side-effects as the reason for discontinuation. Finally, one study reported that 249 
infection or erosion was responsible for 9.4% of participants discontinuing PP (40). 250 
Treatment-specific factors: ICI treatment 251 
There were 7.2% (2.0-24%) of men across ten studies (40, 48, 49, 62-65, 68, 69, 77) who reported 252 
that they discontinued ICI treatment due to difficulty, inability, being unwilling to self-inject or 253 
needle phobia. This was associated with significantly higher rates of discontinuation in one of these 254 
studies (48).  255 
4.11 Condition Specific Factors 256 
ED aetiology 257 
Five studies investigated the relationship between aetiology and PDE5I utilisation (29, 34, 35, 41, 258 
43). Men with psychogenic as opposed to organic (34, 43) or venogenic as opposed to arteriogenic, 259 
diabetic or iatrogenic ED (35), reported significantly higher rates of persistence. Further studies 260 
however, did not replicate these findings (29, 41). In relation to ICI, aetiology that included an 261 
organic component was related to significantly higher rates of discontinuation (49).  262 
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ED severity 263 
Of eight studies on PDE5Is, five found that less severe ED was associated with significantly higher 264 
rates of persistence (36, 37, 42, 43, 47) and adherence (43). However, three studies did not find such 265 
a relationship (29, 41, 46).  266 
ED duration 267 
Five studies investigated the relationship between duration of ED symptoms and PDE5I utilisation. 268 
Findings were conflicting, shorter duration of ED was reported as being related to significantly higher 269 
rates of discontinuation in one study (34), but to significantly higher rates of persistence (43, 45) and 270 
adherence (42) in three studies. Finally, one study found the relationship between ED duration and 271 
treatment utilisation to be non-significant (41).   272 
Comorbid conditions  273 
The effects of comorbid conditions were explored by eight studies on PDE5Is (29, 34, 36, 41, 42, 46, 274 
55, 74) three on ICI treatment (40, 62, 65) and one on PP (40). Across three studies (55, 74, 78) 1.9% 275 
(range: 0.8-3.9%) of men discontinued PDE5Is due to comorbid conditions. A higher proportion of 276 
men suffering with comorbid hypertension were both more persistent and adherent than those 277 
without the condition (42). Similarly, men who had a BMI of ≥ 23 or more indicated significantly 278 
higher rates of persistence (34, 36). Conversely, participants with coronary artery disease (41) or 279 
who had undergone pelvic surgery (36) were significantly more likely to discontinue PDE5Is. Finally, 280 
four studies found no significant relationships (29, 34, 41, 46).  281 
Across two studies (40, 65), 4.4% (range: 3.4-5.5%) of men discontinued ICIs due to comorbid 282 
conditions. A third study, using inferential statistics, reported the relationship as non-significant (62). 283 
4.12 Psychological and Cognitive Factors 284 
Twelve studies explored one or more psychological or cognitive factors in relation to treatment 285 
utilisation, nine on PDE5Is (27, 29, 31, 34-36, 45, 56, 78) and three on ICI (48, 67, 68).   286 
 287 
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Treatment Related Beliefs 288 
In one study PDE5Is were discontinued by 23.4% of men as they caused personal conflict, although 289 
the study does not elaborate on its meaning (56). In addition, fear of drug dependency was reported 290 
by 3% of men (35) and a lack of confidence in medication by 0.1% (29). However, a lack of 291 
confidence in meication was reported as having a non-significant relationship with treatment 292 
utilisation according to one study (31). Potential harm to the heart was reported by 6.5% (range: 4-293 
7.6%) of men across two studies (27, 35) and not being willing for one’s sex life to depend on 294 
medication was reported by 3% (range: 0.4-7.4%) of men across three studies as reasons for 295 
discontinuation (29, 34, 78).  296 
Psychosocial well-being 297 
The effects of psychosocial factors were reported by two studies focussed on PDE5Is (27, 36) and 298 
one on ICI treatment (48). One study reported that 10.1% of men used PDE5Is only in “special 299 
moments” to prolong pleasure or to avoid and/or improve bad performance (27). Similarly, 8.1% of 300 
men reported using PDE5Is to improve their psychological and emotional state (27). A lack of self-301 
esteem or self-confidence was given as a reason for PDE5I discontinuation by 0.8 and 11.4% of men 302 
(27, 36) and significantly higher rates of persistence to ICI treatment were also associated with 303 
higher levels of self-confidence and self-esteem (48).  304 
4.13 Social Factors  305 
Thirty-six studies investigated social factors and their effect on ED treatment utilisation, twenty four 306 
on PDE5Is (27-29, 31, 33-37, 41, 43, 45, 46, 51-55, 57, 58, 61, 73, 74, 78), nine on ICI (40, 48, 49, 62, 307 
64-66, 69, 77), one on US (72) and PP (40). 308 
Cost of Treatment 309 
Across seventeen studies (27-29, 34-36, 43, 45, 46, 52-55, 61, 73, 74, 78) 6.6% (0.6-47.3%) of men 310 
discontinued PDE5Is due to high personal financial cost. Across three studies 4.6% (range: 4.4-5.5%) 311 
of men discontinued ICI treatment (40, 62, 65). Finally, 25.4% discontinued US due to cost (70). 312 
Studies were from a variety of countries including New Zealand (28), Portugal (27) Korea (34, 78), 313 
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Taiwan (45) and the USA (46, 52, 53), where some were multi-national (29, 31, 36, 42, 43, 56) (Table 314 
1).  315 
Related to Partner and Intimate relationship  316 
Twenty-two studies focussed on PDE5Is (27-29, 31, 33-37, 40, 41, 45, 51-53, 55-58, 73, 74, 78) nine 317 
on ICI (40, 48, 49, 62, 64-66, 69, 77), one on US (72) and PP (40) explored couples’ sexual relationship 318 
and treatment utilisation.  319 
The most commonly reported factors were loss of libido or interest in the sexual relationship; 320 
reported by 6.6% (range: 0.6-17.3%) of men across nine studies focussed on PDE5Is (34, 35, 45, 52, 321 
55, 58, 73, 74, 78), 8.8% (range: 6.9–30%) across four studies focussed on ICIs (40, 62, 65, 77) and 322 
8.9% and 6.9% of men using US and PP, respectively (40, 72).  323 
A partner’s lack of interest in the sexual relationship was given as a reason for PDE5I discontinuation 324 
by 5.5% (1.2-9.8%) of men across five studies (27, 34, 45, 58, 74). A lack of emotional readiness for 325 
restoration of sexual activity was a reason for discontinuing PDE5Is for 5.5% (13.1-22.7%) of men in 326 
two studies (34, 78) and conflict within one’s relationship by 4.1% (2.4-5.8%) of men in three studies 327 
(27, 28, 51). Conflict within one’s relationship was also a reason for 1% discontinuing ICI (62). Low 328 
levels of satisfaction with one’s sexual relationship, was associated with significantly higher rates of 329 
ICI discontinuation (49). Conversely, a better quality sexual relationship was associated with 330 
significantly higher rates of ICI persistence (48).  331 
4.14 Behavioural Factors 332 
Seven studies examined the effect of behavioural factors on treatment utilisation; six on PDE5Is (27, 333 
33-37) and one on ICI treatment (49). Most commonly a lack of opportunity to engage in sexual 334 
intercourse was a reason for 0.9% (2-7.3%) of men to discontinue PDE5Is, across three studies (27, 335 
35, 61). A greater number of sexual attempts in the first month of treatment and a higher rate of 336 
pre-treatment sexual activity were both associated with significantly higher rates of PDE5I 337 
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persistence (33, 36). Finally, less frequent masturbation was related to significantly higher levels of 338 
ICI treatment discontinuation (49).  339 
5. Discussion 340 
Rates of treatment discontinuation varied considerably across studies, from 4.4-76.0% for PDE5Is, 341 
18.6-79.9% for ICI, 32.0-69.23% for US and 30% for PP. This may relate in part to limitations in 342 
operational definitions where less than a quarter of studies gave explicit definitions of treatment 343 
utilisation. Where provided, however, variation existed. These findings support a previous call for 344 
standardisation of adherence definitions to enable more accurate comparisons between studies 345 
(26).  Other potential reasons for variation in utilisation rates identified by previous research include; 346 
differences in methodologies, adherence measures, treatment regimens, and patient characteristics 347 
(79).  348 
In relation to barriers and enablers of treatment utilisation, no consistent findings were evident for 349 
demographic factors. However, clinical factors, examined by all studies included in this review, 350 
indicate treatment ineffectiveness and side-effects as the most prevalent reasons given for 351 
discontinuation. 352 
Only twelve studies examined psychological or cognitive factors, which is surprising considering that 353 
psychogenic factors are the cause to some degree of nearly all cases of ED (80). In addition, there is a 354 
large body of research which highlights the importance of patient beliefs in relation to a range of 355 
acute and chronic conditions and their respective treatments (81-83). Such beliefs have been found 356 
to predict adherence in a variety of chronic conditions (84) and are amenable to change which can 357 
improve adherence (85). None of the studies included in this review utilised psychological theory to 358 
guide their investigations, therefore, future research would benefit from employing psychological 359 
theory to advance our understanding of barriers and enablers to ED treatment utilisation.  360 
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A widely reported social factor was treatment cost (n=21), however, it was not explored by any of 361 
the studies using inferential statistics. Therefore, it is difficult to ascertain the extent to which other 362 
factors, such as employment status, play a role. Additionally, studies originated from a variety of 363 
countries involving a variety of health care systems. In the UK, for example, guidance provided by 364 
the Department of Health restricts prescription of ED treatments to those patients who meet 365 
specific criteria, meaning that, for example, those men with ED who additionally suffer with 366 
diabetes, multiple sclerosis or Parkinson’s disease can receive treatment on the NHS for ED (86). 367 
Previously, if a patient did not meet such criteria, then the patient incurred a personal cost for 368 
treatment. However, with the advent of cheaper medicines becoming available (87), in 2014, 369 
legislation was introduced removing the restrictions on NHS prescribing of generic sildenafil. This 370 
enabled HCP’s the ability to prescribe generic sildenafil for all men with ED on NHS prescription (88). 371 
Finally, more recently, Sildenfil has been made available in UK pharmacies for men who wish to 372 
purchase the treatment over-the counter (89). It is beyond the scope of this review to consider the 373 
impact of varying procurement methods on ED treatment utilisation, however, this remains an 374 
important consideration for future research.  375 
Loss of libido in men and their partners and its relationship with ED treatment discontinuation was 376 
also a widely reported social factor. It is possible that loss of libido was underreported as other 377 
factors potentially overlap, such as a lack of emotional readiness for restoration of sexual activity 378 
and conflict within one’s relationship. Furthermore, loss of libido and ED are both symptoms of 379 
testosterone deficiency (90), but studies did not report potential causes of low libido in their 380 
participants. The causes of low or a lack of libido are important considerations for HCP’s to consider 381 
when providing treatment for ED as successful treatment of other conditions such as testosterone 382 
deficiency may influence successful treatment with regards to ED.  Although treatment 383 
ineffectiveness was the most frequently reported barrier to utilisation, operational definitions were 384 
absent. Therefore it is possible that a treatment could potentially be described as ‘ineffective’ due to 385 
other factors such as loss of libido or conflict within one’s relationship. Underlying factors such as 386 
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these may have been overlooked and therefore, future research would benefit from investigating 387 
individual perceptions of ineffectiveness which, in turn, could enable HCPs to provide appropriate 388 
support, potentially reducing discontinuation.  389 
It is important to note that results of the current review indicate that men who reported side-effects 390 
to a HCP were significantly less likely to discontinue treatment. This suggests that there is potential 391 
for HCP’s to influence utilisation rates. As discussed, perceived ineffectivness of treatment has a 392 
subjective element and therefore requires exploration with a given patient. We would 393 
recommended that if men report that their treatment is ineffective, prescribers seek to identify and 394 
clarify any misconceptions patients may have in relation to their treatment. This would enable the 395 
possibility of exploring beliefs about medication with patients where changing treatments or altering 396 
doses in line with any insights that arise could potentially increase ED treatment utilisation. 397 
Additionallly, exploring the quality of patients’ intimate relationships may indicate the necessity for 398 
additional treatments, for example psychosexual counselling, which could potentially work in 399 
conjunction with medication/devices and increase treatment utilsiation.  400 
There were methodological limitations with respect to the studies included. Descriptive statistics 401 
were used by 32 studies and only 8 used multivariate statistics to analyse data. Therefore, a 402 
substantial amount of frequency data was included, which can indicate the prevalence of a barrier or 403 
enabler, but not their unique impact on utilisation when others are taken into account.  404 
There was an absence of reliable and validated measures with respect to rates of treatment 405 
utilisation, as well as barriers and enablers to utilisation. Although there is no ‘gold standard’ to 406 
measuring treatment adherence (91), there are a variety of validated treatment adherence 407 
measures (92). However, existing measures of treatment adherence are potentially unsuitable for 408 
assessing ED treatments; taken predominantly on demand. Therefore, this review highlights the 409 
need for a validated measure of ED treatment utilisation and echoes the call for simple, valid and 410 
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reliable methods for detecting the prevalence and types of non-adherence to enable the possibility 411 
of building effective and targeted adherence interventions (85) .  412 
The methods used to ask men about barriers and enablers to treatment utilisation varied 413 
considerably. Use of open-ended questions may result in some barriers or enablers being under-414 
reported if they are not asked about specifically. In order to understand barriers and enablers to ED 415 
treatment utilisation, future studies would benefit from using a design that are prospective in nature 416 
coupled with the use of validated measures. In addition, analysis of results using multivariate 417 
statistics would enable causes to be established rather than associations.  418 
This review has several limitations. The inclusion of only published manuscripts introduces the 419 
possibility of publication bias and resources dictated that articles were published in English. Due to 420 
the nature of some of the barriers and enablers, allocation to one of the overarching themes was not 421 
always straight forward. For example, loss of libido was classified as a social factor; however, this is 422 
likely to have psychological and/or physiological components. The quality of findings of any 423 
systematic review relies in part on the quality of the studies included and although study quality 424 
varied, 58% were classified as either ‘limited’ or ‘adequate’. In general, there was an under-reporting 425 
of important participant data such as ED duration, ED severity, relationship status, levels of 426 
employment and levels of education. 427 
In conclusion, treatment ineffectiveness, side-effects, the quality of one’s intimate relationship as 428 
well as the cost of treatment emerged as important barriers to treatment utilisation. There is a need 429 
for study designs to be more rigorous as well as a greater focus on the impact of psychosocial 430 
factors. Beliefs about ED and its treatment are potentially modifiable, offering an opportunity to 431 
improve treatment utilisation and the quality of life of both men and their partners. Therefore, 432 
based on the results of this review, future research would benefit from identifying modifiable factors 433 
e.g. beliefs about medication, which could be targeted by interventions to help improve utilisation 434 
through the use of a more theoretically informed, evidence-based approach.  435 
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Alvarez et al. (1998)(63) Europe, South Africa Evaluate the long-term safety and efficacy.  Prospective cohort study Aprostadil 20 mg/mL  6 months 848 70% 
Armstrong et al (1994)(64) N. Ireland To identify factors contributing to patient drop- 
out from an ICI programme. 
Cross-sectional study NR  n/a 30 45% 
Gerber and Levine (1991)(65) USA To investigate erectile response, pain after 
injection and frequency of use.  
Prospective cohort study Aprostadil: 5, 10 or 20 mcg’s M=7 months (2-28 
months) 
72 41% 
Irwin & Kata (1994)(77) USA To determine acceptance and durability of 
treatment. 
Prospective cohort study Aprostadil (mean dosage) = 
23 ug (range 5-30 ug). 
6 months 60 45% 
Kunelius et al (1999)(66) Finland To assess the long-term outcome of treatment 




NR 36 months 69 54% 
Lehmann et al (1999)(48) Switzerland  To clarify the reasons why experience with self-




Alprostadil 2-mL M=16 (3-64 
months) 
86 59% 
Perimenis et al (2001)(67) Greece Compare patient compliance with treatment and 
the dosages used for the management of 
impotence. 
Prospective cohort study  Aprostadil initially 5 – 10 ug  84 months 40 64% 
Polito et al (2012)(68) Italy To assess the rate of compliance in the first 6 
months of a rehabilitation protocol for patients 
undergoing RRPP. 
Prospective cohort study Alprostadil initially 2 – 3 mcg 6 months 273 68% 
Purvis et al (1999)(50) Norway To examine the impact of treatment on libido, 
ejaculatory control, quality of life and treatment 
dependency in men with erectile failure. 
Furthermore to assess the drop-out rate and 
reasons for dissatisfaction with the technique. 
Cross-sectional study Aprostadil (10 ± 20mg), 
papaverine-phentolamine 
(15 mg; 0.5 mg) and Trimix 
(10 mg Aprostadil; 15mg 
papaverine; 0.5 mg 
phentolamine). 
 n/a 766 64% 
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Raina et al (2003a)(57) USA Investigate drug efficacy in patients following RP. Retrospective cohort 
study 
Aprostadil alone (10 or 20 
mg/ml in normal saline), 
high-dose triple therapy (20 
mg/ml Aprostadil +1 mg/ml 
phentolamine +30 mg/ml 
papaverine), or low-dose 
triple therapy (5.88 mg/ml 
Aprostadil +0.59 mg/ml 
phentolamine+ 17.65 mg/ml 
papaverine). 
M=14.5 months 102 73% 
Rowland et al (1999)(49) USA Explore satisfaction with and dropout from ICI 
use. 
Prospective cohort study NR M=9 months 119 73% 
Sung et al (2014)(62) Korea To investigate the rate of withdrawal and its 
associated reasons. 
Cross-sectional Trimix (a mixture of 
prostaglandin E1 18 ug, 
papaverine 48 mg and 
phentolamine 2 mg in 2 mL 
of distilled water). 
18 +/- 23.9 294 82% 
PDE5I medication 
Bai et al (2015)(59) China To compare treatment preference, efficacy, and 
tolerability of sildenafil and tadalafil for treating 
erectile dysfunction (ED)  
Randomised Trial (1) 20‑mg tadalafil and then 
100‑mg sildenafil  
(2) 100‑mg sildenafil and 
then 20‑mg tadalafi 
7 Months 383 91% 
Buvat et al (2013)(31) France, Greece, Portugal, 
Germany, UK 
To evaluate the effects of initiating treatment 
with Tadalafil OaD, Tadalafil PRN, or sildenafil 
PRN on treatment utilisation. 
Randomised Trial  (1) Tadalafil OaD, 5 mg OaD 
(2) Tadalafil PRN, 10 mg PRN 
(3) Sildenafil PRN, 50 mg 
PRN 
median = 4.3 
months 
median = 5.5 










Buvat et al (2014)(29) Germany, France, Italy, 
Greece 
To evaluate treatment continuation, effectiveness 
and tolerability of Tadalafil OaD. 
Prospective cohort study Tadalafil OaD 5-mg 6 months 778 100% 
Cairoli et al (2014)(41) Brazil To characterize persistence and adherence to 
PDE5I on-demand therapy over 6 months 
Prospective cohort study NR 6 months 104 81% 
Carvalheira et al (2012)(35) Portugal  (i) to analyse discontinuation rates of PDE5Is; (ii) 
to identify predictors of discontinuation; and (iii) 
to study the reasons for discontinuation using a 
qualitative methodology 
Mixed methodology NR 36 months 327 68% 
Carvalheira et al (2014)(27) Portugal  (i) To characterize the way men use PDE5I and (ii) 
analyse treatment utilisation, identifying the 
factors that influence PDE5I use. 
Cross-sectional Study NR  n/a 148 65% 
Choi et al (2014)(60) China To investigate the sustainable effect of 5-mg 
alternate-day tadalafil versus 5-mg once-daily 
tadalafil  
Randomised Trial (1) Tadalafil) 5-mg once-
daily (2) Tadalafil) (5-mg 
alternate-day 
3 months 180 61% 
Cimen et al (2009)(73) Turkey Retrospective evaluation of ED patients who were 




NR  n/a 345 55% 
Conaglen & Conaglen 
(2012)(28 
New Zealand To evaluate factors influencing adherence to, or 
discontinuation of, oral ED medications. 
Retrospective cohort 
study 
NR 12 months 155 64% 
El-Galley et al (2001)(51) USA, Saudi Arabia Evaluation of the long-term efficacy of Sildenafil Prospective cohort study NR 24 months 200 54% 
El-Meliegy et al (2013)(42) Saudi Arabia Egypt, United 
Arab Emirates, USA 
To assess on-demand PDE5I treatment 
persistence and adherence over 6 months in men 
with ED. 
Prospective cohort study NR 6 months 493 95% 
Fagelman et al (2001)(52) USA To evaluate the efficacy, side-effects, renewal 
patterns and other relevant practice issues 
related to the use of sildenafil. 
Prospective cohort study Sildenafil 50 mg, increasing 
to 100 mg if necessary.  
6 – 12 months 164 54% 
Green and Martin (2000)(53) USA To evaluate the efficacy and safety of sildenafil in 
patients with ED caused by spinal cord injury and 
multiple sclerosis. 
Prospective Cohort Study NR M=21 months 40 45% 
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Incrocci et al (2003)(54) Netherlands To determine the efficacy of Sildenafil citrate in 
patients with ED after three-dimensional 
conformal external beam radiotherapy. 
Quasi experimental  50 mg for 2 weeks 
increasing to 100 mg if 
necessary. 
24 months 50 64% 
Jiann et al (2006)(45) Taiwan  To assess treatment compliance and reasons for 
dropout. 
Cross-sectional Study NR M=36 months 434 64% 
Kim et al (2014)(34) Korea To identify characteristics of ED patients who 
discontinued PDE5I medication. 
Cross-sectional Study NR  n/a 485 91% 
Kim et al (2015)(32) USA To evaluate whether TAD-OaD provides similar 
efficacy in men with ED who had previously 
demonstrated a partial response to PRN PDE5I 
therapy. 
RCT (1) Placebo,  
(2) Tadalafil 2.5 mg 
(uptitrated to tadalafil 5mg 
after 4 weeks) 
(3) Tadalafil 5mg OaD  
3 months 623 93% 
Klotz et al (2005)(74) Germany To determine the rate of abandonment of 
sildenafil therapy and assess the reasons for 
abandonment. 
Prospective cohort study Sildenafil 50 or 100 mg 6 months 234 41% 
Lee et al (2010)(46) USA To evaluate factors that affect discontinuation in 
men after nerve sparing RAP. 
Prospective cohort study Sildenafil citrate (100 mg) 
three times a week or 
Tadalafil (20 mg) three times 
a week. 
6 months) 53 61% 
Li et al (2016)(76) China To assess the efficacy of tadalafil de-escalation in 
the therapeutic effects of psychogenic ED 
Randomised Trial  (1)  5 mg of tadalafil per day; 
Group 2:  20 mg tadalafil per 
day (for 1 month) followed 
by 10 mg per day (for the 
2nd month)  and 5 mg for 
the third month. 
3 months 86 61% 
Ljunggren et al (2008)(55) Sweden To study long-term compliance among patients 
who were treated according to a “three-drug 
regime” i.e. able to try all 3 PDE5I medications. 
Prospective cohort study NR M=27 months 138 45% 
Mazzola et al (2013)(33) USA  To explore the link between erection hardness 
and treatment adherence. 
Prospective cohort study Sildenafil, 100 mg 17 +/- 4 months 186 82% 
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McMurray (2007)(30) USA To assess the safety and effectiveness of flexible 
doses of Sildenafil 
Prospective cohort study Flexible-doses (25, 50, and 
100 mg) of Sildenafil. 
48 months 979 54% 
Montorsi et al (2004)(56) Italy/Belgium/Netherlands
/Germany/Spain/Canada/
Argentina/Mexico/USA 
To assess the long-term safety and tolerability of 
tadalafil for patients with ED. 
Prospective cohort study  Initial dose was 10 mg 
(Tadalafil) taken as needed 
18-24 months 493 68% 
Raina et al (2003b)(57) USA To evaluate the long-term effect and safety of 
sildenafil citrate for the treatment of ED. 
Prospective cohort study Starting dose was 50 mg, 
which was titrated to 100 
mg if necessary. 
36 months 48 73% 
Ricardi et al (2010)(75) Italy To compare the efficacy and safety of Tadalafil 
PRN 20-mg (arm A) with Tadalafil 5-mg OaD (arm 
B) in patients with ED following radiotherapy for 
prostate cancer. 
Randomised Trial Tadalafil 20 mg PRN (arm A) 
or Tadalafil 5 mg OaD (arm 
B) 
3 months 52 93% 
Roumeguere et al (2008)(36) Austria/Belgium/Denmark
/Greece/Iceland/Netherla
nds/Norway/Sweden 
To determine the effectiveness of Tadalafil and 
the factors associated with the continuation of 
treatment for ED. 
Prospective cohort study Tadalafil 10 or 20 mg  12 months 1567 100% 
Rubio-Aurioles et al 
(2013)(43) 
Brazil, Mexico, Venezuela Investigate the factors that may be predictive for 
PDE5I persistence and adherence. 




Salonia et al (2008a)(58) Italy Assess acceptance of and discontinuation rate 
from ED treatment in patients after bilateral 
nerve-sparing radical retro-pubic prostatectomy. 
Prospective cohort study NR 18 months 51 82% 
Salonia et al (2008b)(37) Italy To explore whether the educational status may 
have a significant impact on the delay before 
seeking first medical help and compliance with a 
suggested PDE5I. 
Prospective cohort study Sildenafil 50 mg, Vardenafil 
10 mg or Tadalafil OaD 10 
mg. 
=/< 24 months) 231 91% 
Sato et al (2007)(47) Japan To study the dropout rate for use of sildenafil 
after initial prescription and during successful 
treatment to clarify their risk factors. 
Prospective cohort study NR 36 months 322 68% 
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Son et al (2004)(78) Korea To investigate the reasons for discontinuations of 
Sildenafil after the successful restoration of 
erectile function. 
Prospective cohort study Flexible Sildenafil doses; 25-
100 mg according to 
patients need and side-
effects 
6 months 156 41% 
Souverein et al (2002)(44) Netherlands  Sildenafil utilization was evaluated in men with 
ED. Further, some determinants of Sildenafil 
discontinuation were identified. 
Prospective cohort study NR M=18 months 317 86% 
Urethral Suppository  
Mulhall et al (2001)(70) USA To determine the consistency of a successful 
response to a urethral suppository (Aprostadil) 
Prospective cohort study Aprostadil 1000 mg M=9 months 68 73% 
Raina et al (2007)(72) USA To obtain baseline and follow-up data of 54 
patients who used medicated urethral system for 
erection for ED associated with RP. 
Prospective cohort study Aprostadil 125 ug or 250 ug 
of urethral suppository. 
M=9 months 56 61% 
Raina et al (2005)(71) USA To assess whether early introduction of Aprostadil 
after RP results in a shorter recovery time for the 




Aprostadil 250 mg flexible to 
500 or 1000 mg dose of 
urethral suppository, if 
needed  




Panach-Navarretea et al 
(2017)(61) 
Spain To describe the medium and long-term 
satisfaction and adherence of pharmacological 
treatments in ED 
Cross-sectional  NR NA 250 85% 
Sexton et al (1998)(40) USA To compare the long-term outcomes of both 
penile prostheses and ICI therapy and determine 
the reasons for discontinuation. 
Prospective cohort study NR M=37 months (PP) 
M=63 months (ICI) 
130 54% 
 700 
ICI: Intracavernousal injection therapy; M: mean; OaD: once a day; PP: penile prosthesis; PRN: on demand; RAP: robotic assisted prostatectomy; RCT: randomised control trial; US: Urethral suppository 701 
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Ethnicity, n(%) Relationship status, n(%) 
Co-morbidities, 
n(%) 
ED Aetiology n,% 
ED Duration, 
months (sd) 
ED severity – 
IIEF n(%) 
ICI treatment 
Alvarez et al. (1998)(63) 52  NR NR NR Neurogenic: 118 (14) 
Vasculogenic: 215 (25) 
Psychogenic: 268 (32) 
Diabetes: 94 (11) 
Other: 30 (3.5) 
Mixed causes: 123 (15) 
54   NR 
Armstrong et al (1994)(64) 50.5  NR NR NR NR NR NR 
Gerber and Levine 
(1991)(65) 
NR NR NR NR NR NR NR 
Irwin & Kata (1994)(77) 64 NR NR NR NR NR NR 
Kunelius et al (1999)(66) 60.5 NR NR NR Vasculogenic: 30  (28) 
Psychogenic: 31 (29) 
Neurologic: 8 (7) 
 
NR NR 
Lehmann et al (1999)(48) 58 (10)  NR NR NR Organic: 52 (60)  
Mixed: 23 (27) 
Psychogenic: 11 (13) 
NR NR 





Ethnicity, n(%) Relationship status, n(%) 
Co-morbidities, 
n(%) 
ED Aetiology n,% 
ED Duration, 
months (sd) 
ED severity – 
IIEF n(%) 
Polito et al (2012)(68) 64.6 (6.5) NR NR NR NR NR M=No ED (=/> 20): 
212 (77.6%)  






Raina et al (2003a)(57) 60.4 (6.3)  NR NR NR NR NR Sev: 68% 
Rowland et al (1999)(49) 58 NR NR NR NR 41 NR 
Sung et al (2014)(62) 61.8 (7.9) NR NR Diab: 82 (27.9), Hyp: 
118 (40.1), CVD: 37 
(12.6), CVA: 11 (3.7), 
Previous RP: 198 (67.3), 
NSRP: 72 (36.4), 











Ethnicity, n(%) Relationship status, n(%) 
Co-morbidities, 
n(%) 
ED Aetiology n,% 
ED Duration, 
months (sd) 
ED severity – 
IIEF n(%) 
PDE5I medication 
Bai et al (2015)(59) 39.94 (11.00) NR NR Diab: 17 (4.4),  
Hyp 19 (5.0) 
Organic: 24 (6.3),  
Mixed: 272 (71.0) 
≥3  to <12 164 (42.8), 
≥12 219 (57.2) 
Mi 131 (34.2), 
Mod 133 (34.7), 
Sev 119 (31.1) 
Buvat et al (2013)(31) 53.03 (11.66)       White 753 (97.8), 
Black/African American 10 
(1.3), Multiple 1 (0.1)   
NR Hyp: 266 (34.5), Hyperl: 
137 (17.8), Diab: 142 
(18.8), BPH: 68 (8.8), 
Dys: 42 (5.4), Osteo: 36 
(4.7), Dep: 36 (4.7), Anx: 
30 (3.9) 
Tadalafil OaD  
Psychogenic: 54 (21.0) 
Organic: 56 (21.8) 
Mixed: 125 (48.6) 
Unknown: 22 (8.6) 
  
Tadalafil PRN  
Psychogenic: 59 (23.4) 
Organic: 65 (25.8) 
Mixed: 106 (42.1) 
Unknown: 22 (8.7) 
 
Sildenafil PRN 
Psychogenic: 62 (23.8)  
Organic: 66 (25.3) 




23.3     Mi 300 (38.9), Mod 
261 (33.9), Sev 204 
(26.5) 
Buvat et al (2014)(29) 57  Caucasian 523(67.2), Other 
4(0.5) 
Married 639(65.9), Partnered/living 
together 120(12.4) 
CVD: 268 (34.5), Hyp: 
260 (33.4), Dysl: 144 
(18.5), Diab: 124 (15.9) 
PS: 89 (11.4), BPH: 49 
(6.3), Hypog:12 (1.5) 
Mixed: 443 (45.7) 
Organic: 286 (29.5) 
Psychogenic: 172 (17.8) 
Unknown: 68 (7.0) 
<3 n=55 (7.1%)  
3-12  n=231(29.7%)  
≥12  n=490(63.1%) 
Mi 160 (20.6), Mod 






Ethnicity, n(%) Relationship status, n(%) 
Co-morbidities, 
n(%) 
ED Aetiology n,% 
ED Duration, 
months (sd) 
ED severity – 
IIEF n(%) 
Cairoli et al (2014)(41) 57.8 (10.9) NR NR Hyp: 54 (51.9), Diab: 25 
(24.0), Ob: 10 (9.6), 
CAD: 4 (3.8), BPH: 7 
(6.7), LUTS: 5 (4.8), 
Hyperl: 13 (12.6) 
Mixed: 48 (47.1) 
Organic: 37 (36.3) 
Psychogenic: 16 (15.7) 
 24 Mi 13 (13.8), Mod 
58 (61.7), Sev 23 
(24.5) 
Carvalheira et al 
(2012)(35) 
56.30 (11.44) NR Married: 65.4% 
Divorced/separated: 18.3%  
Single: 10.4% 
Common law: 3.1% 
Widowed: 2.8% 
NR Venogenic :79 (24.2)  
Arteriogenic: 75 (22.9)  
Iatrogenic: 62 (19.0)  
Psychogenic: 50 (15.3)  
Diabetic: 40 (12.2)  
Neurogenic: 21 (6.4) 
NR NR 
Carvalheira et al 
(2014)(27) 
55.8 (11.11) NR Married: 61.5% 
Divorced/separated: 20.3% 
Single: 12.2% 






Neurogenic: 8%  
Diabetic: 7% 
NR NR 
Choi et al (2014)(60) 56.8 NR NR Underlying disease 42 
(29.1) 
NR NR Mod – Sev 180 
(100) 
Cimen et al (2009)(73) 56 (11.2) NR NR Diab: 21.7%, Hyper: 
16.1%, CVD: 4.7% 





Ethnicity, n(%) Relationship status, n(%) 
Co-morbidities, 
n(%) 
ED Aetiology n,% 
ED Duration, 
months (sd) 
ED severity – 
IIEF n(%) 
Conaglen & Conaglen 
(2012)(28 




Mixed Ethnicity 11 (7) 
Other 8 (5.1) 
NR NR NR NR NR 
El-Galley et al (2001)(51) 58 (10) NR NR NR Radical prostatectomy: 25  
Neurogenic impotence: 12  
Arterial insufficiency: 26  
Diabetes mellitus: 19  
Diagnosed venous leak: 7  
Clinical venous leak: 9  
Peyronie’s disease: 6  
Other: 47 
NR NR 
El-Meliegy et al (2013)(42) 49.6 (12.03) NR NR Hyp: 222 (45), Diab: 209 
(42.4), Ob: 104 142 
(28.8), BPH: 105 (21.3) 
LUTS: 110 (22.3), 
Hyperl: 169 (34.3) 
Tadalafil   
Psychogenic: 66 (19.3) 
Organic: 133 (38.9) 
Mixed: 125 (36.5) 
Unknown: 18 (5.3) 
  
Sildenafil 
Psychogenic: 14 (18.4) 
Organic: 32 (42.1) 
Mixed: 18 (23.7) 
Unknown: 12 (15.8) 
 
Vardenafil 
Psychogenic: 9 (12.2) 
Organic: 30 (40.5) 
Mixed: 28 (37.8) 
Unknown: 7 (9.5) 
 
18  Mi 78 (15.8), Mod 






Ethnicity, n(%) Relationship status, n(%) 
Co-morbidities, 
n(%) 
ED Aetiology n,% 
ED Duration, 
months (sd) 
ED severity – 
IIEF n(%) 
Fagelman et al (2001)(52) 54.1 NR NR NR NR 44 NR 
Green and Martin 
(2000)(53) 
40.4 NR NR NR Multiple sclerosis: 7 
Spinal cord injury: 33 
Quadriplegics: 13  
Paraplegics: 20 
Complete injuries: 14  
Incomplete injuries: 19  
NR NR 
Incrocci et al (2003)(54) 68 NR NR Diab and/or Hyp 13%  NR NR NR 
Jiann et al (2006)(45) 66.8 (9.8) NR NR NR NR NR NR 
Kim et al (2014)(34) 53.6 (11.8) NR Marriage/Co-habit: 416 (85.8) 
Bereavement: 11 (2.3), Divorce: 14 
(2.9) 
Separation: 13 (2.7), Bachelor: 25 
(5.2), Others: 6 (1.2) 
Diab: 58 (12.0), Hyp: 
102 (21.0), Dys: 39 (8.0), 
Ob: 46 (9.5), CAD: 14 
(2.9), BPH: 119 (24.5), 
Arthritis: 13 (2.7), 
Herniated nucleus 
pulposus: 17 (3.5), 
Digestive disorder: 25 
(5.2)  
Psychogenic: 176 (36.3) 
Organic: 309 (63.7) 
<5 years: 276 (56.9) 
5–9 years: 125 (25.8) 
10–14 years: 48 (9.9) 
=/>15 years: 12 (2.5) 
Don’t know/No 
answer: 24 (4.9) 
Mi: 228 (47.0),  
Mod: 224 (46.2) 
Sev: 33 (6.8) 
 
 
Kim et al (2015)(32) 57.6 (10.4) Caucasian: 517 (83.0), 
Black/African American:  88 
(14.1), Asian: 8 (1.3), Other: 9 
(1.4) 
NR NR Psychogenic: 31 (5.0) 
Organic 297 (47.7) 
Mixed 217 (34.8) 
Unknown 78 (12.5) 
<1 year 39 (6.3) 
 ≥ 1 year 584 (93.7) 
Mi/Mod: 123 (19.7) 
Mod: 472 (75.8), 





Ethnicity, n(%) Relationship status, n(%) 
Co-morbidities, 
n(%) 
ED Aetiology n,% 
ED Duration, 
months (sd) 
ED severity – 
IIEF n(%) 
Klotz et al (2005)(74) 60.5 NR NR Hyp: 40%, Diab: 16% Organic: 202 (86) NR M=Mi-Mod  17  
Lee et al (2010)(46) 57.8 (7.0) NR NR NR NR NR Mi 22  
Li et al (2016)(76) 24.55  (3.8)    Psychogenic: 86 (100)  Mi 15 (16.6) 
Mod 30 (33.3) 
Sev 45 (50) 
Ljunggren et al (2008)(55) 60 (7)   NR NR NR Organic: 40 (32%)  
Psychogenic: 23 (18%)  
Mixed: 64 (50%) 
60 NR 
Mazzola et al (2013)(33) 61 (22)  NR Partnered: 63% Hyper: 36%, Dys: 38%, 
CAD: 16%, Diab: 15% 
NR 26 Mi 25%, Mod 45%, 
Sev 30%,  
McMurray (2007)(30) 58.2 White: 873 (89.2), Black: 68 
(6.9), Asian: 8 (0.8), Other: 30 
(3.1) 
NR Hyp: 272 (27.8), Diab: 
213 (21.8), Hyperl: 139 





Montorsi et al (2004)(56) NR  NR NR NR NR NR NR 
Raina et al (2003b)(57) NR NR NR NR NR NR Sev: 68%  





Ethnicity, n(%) Relationship status, n(%) 
Co-morbidities, 
n(%) 
ED Aetiology n,% 
ED Duration, 
months (sd) 
ED severity – 
IIEF n(%) 
Roumeguere et al 
(2008)(36) 
56.5 (11.1) NR Currently has a partner 1504 (96) CHD: 157 (10), Hyp: 674 
(43), Diab: 360 (23), 
Anx/Dep: 219 (14), 
LUTS: 266 (17), Pros: 78 
(5), Ob: 376 (24), PS: 47 
(3)  
Organic :28%  
Mixed: 51%  
Psychogenic: 21% 
>12 N: 78 (5), Mi: 517 
(33), Mod: 392 (25) 
Sev: 580 (37) 
Rubio-Aurioles et al 
(2013)(43) 
53.2 (12.4) NR NR Hyp: 157 (30.7), Diab: 
106 (20.7), Ob: 95 
(18.6), BPH: 81 (15.9), 
LUTS: 75 (14.7), Hyperl: 
62 (12.2) 
Mixed: 232 (45.6) 
Organic:168 (33.0) 
Psychogenic: 94 (18.5) 
20 Mi: 114 (22.8), 
Mod: 272 (54.3) 
Sev: 115 (23.0) 
Salonia et al (2008a)(58) 51.8 (12.7)  NR No stable sexual relationship: 38 
(16.45) 
Stable sexual relationship  >12 
months: 193 (83.5) 
NR NR NR M=Mi-Mod: 13.75  
Salonia et al (2008b)(37) 53; 10.3 51.4; 
13.5 





Ethnicity, n(%) Relationship status, n(%) 
Co-morbidities, 
n(%) 
ED Aetiology n,% 
ED Duration, 
months (sd) 
ED severity – 
IIEF n(%) 
Sato et al (2007)(47) NR NR NR Diab: 55 (5.3), Hyp: 102 
(9.4), CVD: 13 (1.3), IHD: 
2 (0.2), AS: 6 (0.6), CBD: 
20 (1.9), Dep: 19 (1.8), 
SCI: 12 (1.2), PC: 19 
(1.8), IO: 17 (1.6) 
NR NR Mi: 291 (28.1), 
Mod: 352 (34.0), 
Sev: 393 (37.9) 
Son et al (2004)(78) 54.6 NR NR BPH: 33 (21), Diab: 26 
(17), Hyp: 17 (11) CVA: 4 
(3), Others: 4 (3) 
NR 28.8 M-Mod: 16.23 
(mean) 
Souverein et al (2002)(44) 57.2 (10.74) NR NR NR NR NR NR 
Urethral Suppository 
Mulhall et al (2001)(70) 46.5 (14.6)  NR NR Diab: 11% , Hyp: 29%, 
Hyperch: 21%, A History 
of cigarette smoking: 
31%  
NR NR NR 
Raina et al (2007)(72) 55.6 (3.78) NR NR NR NR NR Sev: 19.65 (mean)  






Ethnicity, n(%) Relationship status, n(%) 
Co-morbidities, 
n(%) 
ED Aetiology n,% 
ED Duration, 
months (sd) 
ED severity – 
IIEF n(%) 




NR NR Hyp: 115 (46), Diab: 70 
(28), Dys: 92 (36.8) 
Smkr; Yes 79 (31.6)/No 
71 (28.4)/Former smkr 
97 (38.8),  
CHD: 27 (10.8), Ldis: 24 
(9.6), VasD: 14 (5.6), 
DigD: 19 (7.6), Endo: 27 
(10.8), Neuro: 22 (8.8); 
OncH: 27 (10.8), PS: 16 
(6.4) 
NR NR NR 
Sexton et al (1998)(40) 58.5 NR NR NR NR NR NR 
Anx: anxiety; AS: Arterial sclerosis; BPH: Benign prostatic hyperplasia; CAD: Coronary artery disease; CBD: Cerebrovascular disease; CHD: Coronary heart disease; CVA: Cardiovascular accident; CVD: cardiovascular 703 
disease; Dep: depression; Diab: diabetes; DigD: Digestive disease; Dys: Dyslipidaemia; Endo: Endocrinopathy; Hyperch: Hypercholesterolemia; Hyp: hypertension; Hyperl: hyperlipidaemia; Hypog: Hypogonadism; IHD; 704 
Ischemic heart disease: IO: Intrapelvic operation; LUTS: Lower Urinary Tract Symptoms; Ldis: Lung disease; M: mean; Mi: mild; Mod: moderate; Neuro: Neuropathy; N: normal; NR: Not recorded; NR; Ob: obesity; 705 
Onco: Oncologic History; Osteo: Osteoarthritis; PC: Prostate cancer; PS: Pelvic surgery; RP: radical prostatectomy; RPS: radical pelvic surgery; RT: radiotherapy; Sev: severe; SHIM: Sexual health inventory for men; 706 
NSRP: Nerve sparing radical prostatectomy; Pros: Prostatectomy; SCI: Spinal cord injury; Sev: Severe; Smkr: Smoker; VasD: Vascular disease707 
42 












Description of Utilisation Measure 
% Adherent (A), persistent (P) 
discontinued (D) 
ICI treatment 
Alvarez et al. 
(1998)(63) 
PD Reasons for discontinuation were 
collected monthly. 
NR PD After each injection: date, time, volume of 
injection and dose were recorded by the 
patient. 
34%  (D)  
Armstrong et al 
(1994)(64) 
SRQ Qs:  Reasons for withdrawal from 
treatment were collected via predefined 
questions. 
NR SRQ Qs: covering home injection use including 
period of time.  
64%  (D)  
Gerber and Levine 
(1991)(65) 
Cons Patients returned every 3 months and 
were questioned regarding erectile 
response, pain after injection and 
frequency of use. 
NR Cons Qs: covering frequency of prostaglandin E1 
use. 
72%  (D)  
Irwin & Kata 
(1994)(77) 
Cons Patients were given monthly follow-up 
visits scheduled to evaluate the patients' 
acceptance and usage patterns 
NR NR Monthly follow-up visits to evaluate patients' 
acceptance and usage pattern. 
60%  (D)  
Kunelius et al 
(1999)(66) 
SRQ Qs: Patients were invited to a check-up 
after three years after they had been 
started on ICI treatment and were sent a 
questionnaire prior to the appointment.  
NR SRQ Qs: aspects of sexual function and possible 
problems with Aprostadil self-injection. 
46%.4 (D)  
Lehmann et al 
(1999)(48) 
Int & Cons Included objective and subjective 
variables which included barriers to 
treatment use. 
NR Int & Cons Qs: covering the number of injections used. 20%  (D)  
Perimenis et al 
(2001)(67) 
NR NR NR NR NR 42.5%  (D)  
Polito et al (2012)(68) SRQ Qs:  multiple choice questions including: 
lack of, disappointment with the effects, 
Injection pain/problems with the injection 
(difficulty/fear), Cost of the drug. 
NR NR NR 18.6%  (D)  
Purvis et al (1999)(50) SRQ Qs: Twenty eight questions were asked 
which were multiple choice in the majority 
of cases. 













Description of Utilisation Measure 
% Adherent (A), persistent (P) 
discontinued (D) 
Raina et al 
(2003a)(57) 
NR NR NR SRQ, CR Data collected: treatment effect, frequency of 
use, duration of erection following penile 
injections and side-effects. 
52%  (D)   
Rowland et al 
(1999)(49) 
SRQ Qs: including as section for participants 
who had discontinued ICI treatment.  
NR SRQ Qs: items pertained to how ICI was used, its 
effectiveness, and the patient's general 
satisfaction. 
40%  (D)  
Sung et al (2014)(62) TS Participants were asked about reasons for 
discontinuation.  
NR TS Qs: multiple responses. 79.9%  (D)  
PDE5I medication 
Bai et al (2015)(59) NR NR NR NR NR tadalafil 20mg: 13.7% (D) 
Sildenafil 100‑mg: 10.3% (D) 
Buvat et al (2013)(31) Cons Time to discontinuation was measured by 
the number of days from randomization 
up to discontinuation of treatment. 
Secondary outcomes included patients 
who switched and discontinued treatment 
and were asked about reasons for 
switches and discontinuations. 
NR Cons NR Tadalafil OaD:52% (D)  
Tadalafil PRN:42% (D)  
Sildenafil PRN:67% (D)  
Buvat et al (2014)(29) TS Patients who had no visit within 4–6 
months after baseline were followed up 
with a telephone follow-up call. 




Cons            A telephone follow-up call was performed if a 
patient had no visit within 4–6 months after 
baseline. 
13.8%  (D)  
Cairoli et al 
(2014)(41) 
SRQ A questionnaire administered at 1, 3, and 
6 months post baseline. 
P=≥ 1 dose 








PAQ Qs: drug administration, dosing compliance, 
erectile function, sexual 
performance/satisfaction, relationship status.  
70.2% (A) 
69.2% (P)  
Carvalheira et al 
(2012)(35) 
TS A telephone interview involving a 
comprehensive, detailed questionnaire 
which included two open ended 
questions: (i) How did you take the 
inhibitor?; and (ii) What reasons led you to 
stop medication? 
NR SRQ Qs: quantitative and qualitative variables and 
including frequency and duration of PDE5 use. 













Description of Utilisation Measure 
% Adherent (A), persistent (P) 
discontinued (D) 
Carvalheira et al 
(2014)(27) 
SRQ Qs: 29-item questionnaire including open 
ended questions with regards to 
utilisation of PDE5Is.  
P=Continued 
use 
SRQ Qs: demographics, type of PDE5i and 
frequency of use, other previous treatments, 
side-effects, expectations regarding the 
treatment, and partner involvement 
100% (P)  
Choi et al (2014)(60) NR NR NR NR NR Tadalafil OaD: 18.9% (D) 
Tadalafil alternate-day: 21.1% (D) 
 
Cimen et al 
(2009)(73) 
TS Patients were called by phone and asked 
to answer questions on the phone 
including questions regarding reasons for 
discontinuation.  
NR Int Qs: PDE5 inhibitor usage status (current 
using/stopped using), patient satisfaction, 
reasons of treatment interruption 
(inadequate efficacy, treatment expenses, 
adverse effects, etc.), drug shift (interchange 
between different PDE5 inhibitors) and 
satisfaction with the new drug were 
interrogated. 
32.8%  (D)  
Conaglen & Conaglen 
(2012)(28 
Int The interviewer followed a question 
schedule that sought details of frequency 
of usage and preference for the drugs 
available to participants. Reasons for that 





Int Qs: details of frequency of usage and reasons 
for discontinuation of use. 
33%  (D)  
El-Galley et al 
(2001)(51) 
TS Participants were contacted by telephone. 
Patients who ended treatment were asked 




TS NR 48%  (D)  
El-Meliegy et al 
(2013)(42) 
SRQ Outcomes were assessed at baseline and 
at 1, 3, and 6 months after treatment 
initiation. 
 
P=≥ 1 dose 








PAQ NR 59.6%  (A) 
64.9 (P)  
Fagelman et al 
(2001)(52) 
SRQ Qs: At follow-up visits, the patients were 




on renewal  
SRQ, Int Qs:  demographics, comorbid conditions, 
duration of ED, length of time taking 
sildenafil, number of tablets taken, maximum 
dose, efficacy, safety, satisfaction, and others. 













Description of Utilisation Measure 
% Adherent (A), persistent (P) 
discontinued (D) 
Green and Martin 
(2000)(53) 
SRQ / TS The initial forty patients were followed for 
a two-year interval either by follow-up 
clinic visits or telephone interviews. 
NR SRQ / TS At follow-up clinic visits or telephone 
interviews. 
32.5%  (D)  
Incrocci et al 
(2003)(54) 
SRQ Qs: evaluate their current sexual 
functioning and to ask about sildenafil 
use. 
NR SRQ Qs: current sexual functioning and use of 
sildenafil. 
76% (D)  
Jiann et al (2006)(45) SRQ Qs: multiple choice questions in regard to 
reasons for discontinuation. 
NR SRQ Qs: marital status, ED duration, frequency of 
sexual intercourse, history and current status 
of usage. 
57% (D)  
Kim et al (2014)(34) SRQ Qs: questionnaire had multiple choice 
questions regarding discontinuation. 
D=not taken 
PDE5i in the 
past 1 year 
SRQ Qs: characteristics and treatment of ED. 23.9% (D)  
Kim et al (2015)(32) NR NR NR NR NR Placebo: 9.1% (D) 
Tadalafil 2.5 mg (pptrated: 10.1% (D) 
tadalafil 5mg OaD: 8.7% (D) 
Klotz et al (2005)(74) TS The reasons for abandonment were 





PR NR 31% (D)  
Lee et al (2010)(46) TS Reasons for discontinuing PDE5I therapy 




NR Compliance measured at two different time 
points: at 2 months and again at the 6 month 
follow-up after. 
72% (D)  
Li et al (2016)(76) NR NR NR NR NR Tadalafil 5 mg: 4.4% (D) 
Tadalafil de-escalation: 4.4% (D) 
Ljunggren et al 
(2008)(55) 
TS Participants were contacted by telephone 
and asked questions regarding reasons for 
discontinuation. 
NR Int Qs: current treatment, frequency of use, 
change of treatment, reason for change, and 
reason for discontinuation. 
14.2% (D)  
Mazzola et al 
(2013)(33) 
Cons On follow-up, patients were questioned 




NR Qs:  regarding continued use of PDE5Is. 67%  (P)  
McMurray (2007)(30) NR At yearly intervals changes in dosing or 
temporary or permanent discontinuation 
were recorded.  
NR PD Compliance was assessed by medication 














Description of Utilisation Measure 
% Adherent (A), persistent (P) 
discontinued (D) 
Montorsi et al 
(2004)(56) 
Cons At patient visits, blood pressure and pulse, 
adverse events, concomitant medications 
and the reason for dose modification were 
recorded.  
NR Cons NR 21% (D)  
Raina et al 
(2003b)(57) 
SRQ Qs: focussed on sexual satisfaction of the 
patients’ spouses/partners 3 years after 
the first survey to assess long-term 
efficacy and compliance.  
NR CR Data collected: drug efficacy, dose, frequency, 
compliance, return of erections, new side-
effects. 
27% (D)  
Ricardi et al 
(2010)(75) 
NR NR P=taking at 
least 70% of 
doses 
NR NR Arm A (20-mg tadalafil PRN): 86% (P) 
Arm B: (tadalafil 5-mg OaD): 100% (P) 
Roumeguere et al 
(2008)(36) 
SRQ Qs: At 1, 6, and 12 months, patients 
completed the IIEF-EF domain 
questionnaire, EDITS and the relationship 
questionnaire, and indicated whether 





Quest Qs: Tadalafil utilisation in the past 4 weeks: 
the number of tablets, dosage, and tolerance 
were recorded.  
16% (D)  
Rubio-Aurioles et al 
(2013)(43) 
SRQ Qs: Patients provided assessments of drug 
administration and dosing compliance, 
erectile function, sexual performance and 
satisfaction, and relationship status at 1, 
3, and 6 months following the initiation of 
treatment. 
P=≥ 1 dose 
taken within 










PAQ administered to patients at 1, 3, and 6 
months after treatment initiation.  
67.5% (A)  
66.5% (P)  
Salonia et al 
(2008a)(58) 
SRQ Qs: At the 18-mo follow-up, patients were 
asked to complete a multiple-choice 
global assessment questionnaire (GAQ) 
regarding specific reasons for eventual 
therapy discontinuation. 
NR SRQ Patients were asked to complete a multiple-
choice GAQ  
72.6% (D)  
Salonia et al 
(2008b)(37) 
Clin, demog data Patients were subdivided into two groups 
according to their compliance. 
NR Cons Data gathered included patient compliance 
with the suggested PDE5. 













Description of Utilisation Measure 
% Adherent (A), persistent (P) 
discontinued (D) 
Sato et al (2007)(47) Clin, demog data Reasons for discontinuation were not 
asked about due to privacy concerns of 
the authors, however, significant risk 
factors for the dropout during successful 
treatment were analysed. 
NR SRQ, Int, Cons NR 48% (D)  
Son et al (2004)(78) TS, CR Six months after the first sildenafil 
prescription, compliance to medication 
and the reasons for discontinuation were 
reviewed by chart or surveyed by 
telephone.  
 
NR TS, CR Compliance to medication and the reason for 
discontinuity were reviewed by chart or 
surveyed by telephone.  
34.6% (D)  
Souverein et al 
(2002)(44) 
PR The date of sildenafil discontinuation was 
defined as the last sildenafil prescription 
date plus the number of tablets 
dispensed. 
D = (1) no 




(3) 6 months 
between the 
last refill and 
the end of 
follow-up. 
PR Sildenafil use during follow-up was assessed 
using information on the number of Sildenafil 
refills during follow-up 
45% (D)  
Urethral Suppository 
Mulhall et al 
(2001)(70) 
SRQ Qs: to determine whether they were 
continuing to use MUSE as a treatment. 
Those who had discontinued therapy were 
asked to complete a questionnaire 
regarding the reasons for stopping.  
NR SRQ Qs: to determine whether they were 
continuing to use MUSE as a treatment. 
69.2% (D)  
Raina et al (2007)(72) NR NR NR NR NR 32 (D)  
Raina et al (2005)(71) NR NR NR CR Data gathered: treatment effect, frequency of 
use, duration of erection following treatment 
and side-effects. 




TS To collect information about the use 
(including time of use) and dropout 
(including reason) of the prescribed 
treatment. 
NR TS To collect information about the use 
(including time of use) and dropout (including 
reason) of the prescribed treatment. 
1st PDE5I: 62.07% (D) 
Other PDE5I: 41.94% (D) 
US: 69.23% (D) 













Description of Utilisation Measure 
% Adherent (A), persistent (P) 
discontinued (D) 
Sexton et al 
(1998)(40) 
TS Telephone interviews were conducted 
with all patients to determine levels and 
frequency of sexual activity, current form 
of therapy and reasons for discontinuing 
therapy, side-effects and overall 
satisfaction. 
NR NR NR ICI:59%(D) 
PP:30%(D)  
CR: chart review; Cons: consultation; Int: interview; NR: not reported; PAQ: persistence adherence questionnaire; PD: patient diaries; PR: prescription records; Qs: questions; Quest: questionnaire; SRQ: self-report 709 





Table 4: Treatment barriers and enablers 714 










Being of older age PDE5I (-): 43 (0): 34,37,41,45,46,47 
(-): 29,36,44 
(+): 35,42  
ICI  (0): 48,49,50 
Education 
Higher level of education PDE5I  (0): 41,42 
(+): 34,37,43(P, not A),  
 
Employment 
Being in FT employment PDE5I  (0): 29   





l Related to Treatment 
Medication Ineffective PDE5I  (-): 27,28,29,30,31,32,35,36,43,45,46,51,52,53,54,55,56,57,58,59,60,61 31; 
- Hardness of erection  
(0): Tad OaD Vs Sild PRN Vs Tad PRN 
- Duration of erection:  
(0): Tad OaD vs. Tad PRN 
(+): Tad OaD sig increased P compared to Sild PRN  
(+): Tad PRN sig increased P compared to Sidl PRN  
ICI (-): 40,61,62,63,64,65,66,67,68,69, (-): 49 
US (-): 61,70,71,72  
PP (-): 40  
Side-effects/Fear of side-effects PDE5I (-); 27,29,30,32,34,36,46,51,52,54,55,59,60,61,73,74,75,76 (0): 31 (between PDE5Is) 
(+): 35; (Men who reported side-effects were less likely to discontinue 
treatment) 
(-): 45 
ICI (-): 40,61,62,64,65,66,67,68,69,77  (0): 48 
(-): 49 
US (-): 61,71,72  
PP (-): 40  
Medication lacks spontaneity PDE5I (-): 34,35,78  
ICI (-): 40, 62  
US (-): 70  
Specific to PDE5I Treatment 
Initial treatment PDE5I  (0): 41 
Having a history of ED treatment utilization PDE5I  (0): 62 
(+): 44 
50 
 Factor TT Descriptive results Inferential results 
 
Using; Tadalafil/Sildenafil or Vardenafil PDE5I  42;  
(0): Tad Vs Sild 
(0): Tad Vs Sild  
(+): Using Sild at initial prescription rather than Vard  
43;  
(0): Sild Vs Vard  
(0): Sild Vs Vard (0);  
(+): Tad sig increased utilisation compared to Sild (P/A) 
Able to tolerate treatment at 1 month PDE5I  (+): 36; Having good toleration for treatment after 1 month was 
associated with sig continued utilisation.  
Higher incidence of trying  dose titration  PDE5I  (+): 45 
Having a dose greater than 50mg  PDE5I  (+): 45 
Short window of time in which the drug is effective PDE5I  31;  
(0): Tad OaD Vs Tad PRN  
(+): Tad OaD sig increased utilisation compared to Sild PRN (P) 
(+): Tad PRN sig increased utilisation compared to Sild PRN  
Slow onset of action PDE5I  (0): 31 (Tad OaD Vs Sild PRN Vs Tad PRN) 
Specific to ICI Treatment 
Administration ICI (-): 40,49,62,63,64,65,68,69,77 (-): 48 
Type of vasoactive substance ICI  (-): 49 
Disposable 1ml syringe  ICI (0): 50  
Fully automatic RFSU pistol  ICI (0): 50  
Manual Injection (d-penn)  as opposed to semi-automatic BD pistol ICI (0): 50  
Using papaverine-phentolamine (15 mg; 0.5 mg)  ICI (0): 50  
Using;Low dose Aprostadil (0 ± 10 mg)/High dose Aprostadil (0 ± 20 
mg)/TRIMIX/D-penn Aprostadil 
ICI (0): 50  
Condition Specific Factors 
Aetiology   PDE5I (+): 43 (psychogenic associated with continuation) (0): 29,41 
(-): 34 (psychogenic associated with discontinuation) 
(+): 35 (venogenic associated with continuation compared to 
arteriogenic /diabetes/iatrogenic) 
ICI  (-): 49 (ED including  an organic component) 
Having more severe levels of ED  PDE5I   (0): 29,41,46 
(-): 36,37,42,43,47 
A shift of =/> 2 or a score of 4 on the erection hardness score (EHS) PDE5I  (+): 33 
Shorter Duration of ED symptoms PDE5I  (-): 34 
(+): 43 (≥ 4 years versus <1 year; P=+, A=0),42 (<1 year P=0, A=+), 45 
(0): 41 (P=0, A=0) 
Comorbidities 
Due to the effects of co-morbidities  PDE5I (+): 42 (Hypertension) 
(-): 55,74 (tumor/hip prosthesis),78 
(0): 29,46 (BMI score/Charlson Comorbidity Index score). 
34;  
51 
 Factor TT Descriptive results Inferential results 
 (0): Number of comorbidities/Stress/Smoking/alcohol 
(+): Sig increase in utilisation by those of higher weight and those with a 
BMI of ≥ 23 
41;  
(0): Diabetes Mellitus/Dyslipidemi/Hypertension/Depression 
(+): Those with Coronary artery disease had sig higher rates of 
utilisation. 
(+): 36 (Sig increase in utilisation by those with  pelvic surgery) 
 ICI (-): 40,65 
 
(0): 62 (diabetes mellitus/hypertension/cardiovascular 
disease/cerebrovascular attack/previous radical pelvic surgery including 
prostatectomy and cystectomy/unilateral or bilateral nerve sparing 
prostatectomy/previous pelvic radiotherapy) 
PP (-): 40  
Illness (ongoing health issues, deteriorating health  or recent 
injuries or operations 
PDE5I (-): 28,36  
ICI (-): 63,64  
Other medications and treatments 
Due to other Medications and Treatments PDE5I (-): 34 44;  
(-): incontinence materials/antidepressants/nitrate therapy/Insulin 
(0): antihypertensive agents/oral anticoagulants/low dose acetylsalicylic 
acid/benign prostatic hyperplasia products 
(+): Lipid-lowering drugs 
Other clinical factors 
Type of physician  PDE5I  31; 
(0): Endocrinologist/diabetologist/urologist/Other 
(+): diagnosed by a GP rather than a urologist sig higher utilisation. 
-Presence of erections prior to treatment 
-Low response during psychophysiological screening (investigation 
of pharmacological 
effects on sexual response). 
-Lack of spontaneous erections 
ICI  (-): 49 
Penile rigidity adequate for sexual intercourse ICI  (+): 62 

































 Treatment Related Beliefs 
Lack of confidence in medication PDE5I (-): 29 (0): 31 (Tad OaD/Tad PRN/Sild PRN) 
Fear of drug dependency PDE5I (-): 35  
F ar that medication is harmful for the heart PDE5I (-): 27,35  
Averse to taking medication PDE5I (-): 27  
Medication caused personal conflict PDE5I (-): 56  
Don't want to take a pill everyday PDE5I (-): 29 31; 
(0): Tad PRN vs Sild PRN 
(-): Tad OaD sig increased discontinuation compared to Tad PRN/Sild 
PRN  
52 
 Factor TT Descriptive results Inferential results 
Prefer a pill every day, not on demand PDE5I  31; 
(0): Tad PRN vs Sil PRN 
(+): Tad OaD sig increased utilisation compared to Sild PRN/Tad PRN 
Not willing for sex life to depend on medication/medication 
controls sex life 
PDE5I (-): 29,34,78 31;  
(0): Tad PRN vs Sild PRN 
(0): Tad OaD vs. Tad PRN 
(-): Sild PRN sig increased discontinuation compared to Tad OaD 
 
Inconvenience/embarrassment in obtaining medication PDE5I (-): 27,45  
Forgetting to buy or to get medical prescription PDE5I (-): 27  
Satisfaction with treatment ICI  (+): 48 
Disappointed with treatment ICI (-): 67,68  
Would recommend treatment to a friend ICI  (+): 48 
Psychosocial Well-being 
Lack of self-confidence/self-esteem PDE5I (-): 27,36  
ICI  (-): 48 
Improve Sexual performance PDE5I  (+): 27 




 Cost of Treatment 
Cost PDE5I (-): 28,27,29,34,35,36,43,45,46,52,53,54,55,61,73,74,78  
ICI (-): 40,62,65,  
US (-): 70  
Related to Partner and Intimate relationship 
Loss of libido/interest in sex PDE5I (-): 34,35,45,52,55,58,73,74,78  
ICI (-): 40,62,65,77  
US (-): 72  
PP (-): 40  





Lack of emotional readiness for restoration of sexual activity PDE5I (-): 34,78  
Higher level of Partners sexual activity PDE5I  (0): 27 
Conflicts within one’s relationship  PDE5I (-): 27,28,51  
ICI (-): 62  
Low satisfaction with sex life ICI  (-): 49 
Better quality of sexual relationship ICI  (+): 48 
Person within the dyad who most often initiated sexual activity ICI  (0): 49 
Partner Related 
Partner’s difficulty in accepting treatment PDE5I (-): 27,29,36 (0): 31 
ICI (-): 66  
Partner satisfaction with treatment (reported by patient) ICI  (+): 48 
Partner aware of and involved in the use of treatment PDE5I  (+): 27 
53 
 Factor TT Descriptive results Inferential results 
Having no partner PDE5I (-): 28,36,53,57 (+): 33 (having a partner) 
ICI (-): 40,64,69,77  
PP (-): 40  
Marital Status/Relationship Status PDE5I  (0): 34,37,41 
ICI  (0): 49 
Living with partner PDE5I  (0): 34 
Longer duration of living arrangement  PDE5I  (-): 31 
Length of marriage/relationship  PDE5I  (0): 34,37 
ICI  (0): 49 
Geographical distance from partner PDE5I (-): 27  
Partner being of younger age (=/>10 years younger) PDE5I  (0): 34 
(+): 33 







l Help seeking 
Length of time before seeking help for ED PDE5
I 
 (0): 37 
Personal behavior 
Lower frequency of masturbation  ICI  (-): 49 
Related to sexual relationship 
Lack of opportunity for sexual intercourse PDE5I (-): 27,35,61  
ICI (-): 61  
US (-): 61  
Pre-treatment sexual activity ( =/>4 times per month) PDE5I  (+): 33 
Greater No of sexual attempts in the first month of treatment PDE5I  (+): 36 
Life style 
Level of exercise PDE5I  (0): 34 
Key: A=adherence; OaD=Once a day; P=persistence; PRN=On demand; Sild=Sildenafil; Tad=Tadalafil; Vard=Vardenafil; (-) = Barrier to treatment utilisation; (+) = Enabler of treatment utilisation; (0) = Not 715 
significant  716 
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intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
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Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  N/A 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  N/A 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  N/A 
56 
 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy makers).  
15-18 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
18 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  18 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the 
systematic review.  
18 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): 
e1000097. doi:10.1371/journal.pmed1000097  
For more information, visit: www.prisma-statement.org.  




1.1.1 Systematic Review Search Terms 
General Terms 
Erectile Dysfunction Adherence Treatment for ED 
Erectile Dysfunction* Medication AND (adher* OR -use OR taking) PDE5 Inhibitor* 
Impoten* (complian* OR non-complian*) Phosphodiesterase type 5 inhibitor* 
penis erection* (adhere* OR non-adhere*) Sildenafil Citrate (Viagra) 
male erectile disorder* (persistence OR non-persistence) Tadalafil (Cialis) 
Sexual dysfunction* Patient complian* Vardenafil (Levitra) 
Male reproductive disorder* Non-fulfilment PDE5I  
Sex disorder* Drug-use Uprima 
Penile Erection* Mean possession ratio Intracavernosal injection* 
Erection* Medication possession ratio Alprostadil pellet 
 Treatment refusal Vacuum device 
 Uptake  Viagra 
 adheren*  Cialis 
 non?adheren* Levitra 
 persist* or non?persist* penile prosthesis  
 complia*  Psychosexual counselling 
 non?complian*   Apomorphine hydrochloride 
 Drug utilization Medicated urethral system for erections 
(MUSE) 
 Health rationing Viridal duo 
  Caverject 
  Caverject dual chamber 





Embase 1974 to 2015 July 
Erectile Dysfunction Adherence Treatment for ED 
Erectile dysfunction Medication compliance Phosphodiesterase V inhibitor 
Impotence  Patient compliance  Sildenafil 
Penis erection Compliance  Vardenafil 
Sexual dysfunction Drug utilization Apomorphine 
 Drug use intracavernous drug administration 
 Treatment refusal prostaglandin E1 
  Tadalafil 
  penis prosthesis 
  prostaglandin E1 
Ovid MEDLINE(R) 1946 to 2015 July 
Sexual dysfunction, Physiological  Medication Adherence Alprostadil 
Sexual dysfunction, Psychological Patient Compliance penile prosthesis 
Sexual dysfunctions, Psychological Compliance Apomorphine 
Penis Treatment Refusal  
Penile Erection Drug Utilisation  
AMED (Allied and Complementary Medicine) 1985 to July 2015 
Sex disorders male Patient compliance Enzyme inhibitors  
Impotence Treatment refusal Sex Counselling 
Sexual dysfunctions Patient acceptance of health care Phosphodiesterase 5 Inhibitors 
Penis  Penile prosthesis 
Genital diseases, male  Apomorphine 
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  Alprostadil 
HMIC Health Management Information Consortium 1979 to July 2015 
Male reproductive disorders Drug compliance  
Impotence Patient compliance  
Penis Drug Consumption  
Sex disorders Drug administration  
 Patient non-compliance  
 Patient participation  
 Patient response to treatment  
 Decision making  
 Health rationing  
 Patient consent to treatment  
Cochrane Central Register of Controlled Trials  
Erectile dysfunction Medication adherence Phosphodiesterase 5 Inhibitors 
Sexual dysfunction, Psychological Compliance Penile prosthesis 
Sexual dysfunction, Physiological Patient compliance Apomorphine 
Penis Treatment refusal Alprostadil 
Health Technology Assessment 2nd Quarter 2015 
Impotence Patient compliance Phosphodiesterase Inhibitors 
Sexual dysfunction, physiological  Treatment Outcome Penile prosthesis 
Penile Erection Drug utilization  Alprostadil 
 Decision making   
 Health care rationing  
CINAHL plus with full text®  
Impotence Medication compliance Phosphodiesterase Inhibitors 
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Sexual dysfunction, Male Patient compliance  Sildenafil 
Penile erection Treatment refusal  Tadalafil 
Penile prosthesis Drug utilization Vardenafil Hydrochloride 
 Decision making, patient penile prosthesis 
  Couple counselling 
  Sexual counselling 
PsychARTICLES® 
Erectile Dysfunction Treatment compliance Phosphodiesterase 
Erection (penis) Treatment refusal  Sildenafil 
Male genital disorders Decision making  Apomorphine 
PsychINFO®  
Erectile dysfunction Treatment compliance Phosphodiesterase 
Erection (penis) Treatment refusal  Apomorphine 















Barrier to treatment utilization 
Descriptive results 
(n (%) reporting reason for 
discontinuation unless otherwise 
stated) 
Barrier to treatment utilization 
Inferential results 
Enabler of treatment 














Being of older age PDE5I Rubio-Aurioles (2013)#  
(P) Higher rates of persistence in younger 
men (mean age of 52.3 years versus 54.9 
years for non-persistent patients). 
(A) Higher rates of adherence in younger 
men (mean age of 52.1 years versus 55.5 
years for non-adherent patients). 
Buvat (2014):  
>65 y significantly higher rates of 
discontinuation than those ≤65 y 
(p=0.038). 
Roumeguere (2008):  
>60 y significantly higher rates of 
discontinuation than those 51-60 y (OR 
= 1.88; 95% CI: 1.18–2.99; P = 0.008)  
Souverein (2002): 
 =/>60 y significantly higher rates of 
discontinuation than <60 y (RR 1.71 
(95% CI: 1.20 – 2.44). 
 
Carvalheira (2012)  
Older men less likely to discontinue (OR 
= 0.956, p =0.005). 
 
El-Meliegy (2013)#  Older men were 
likely to be both more persistent (P) (OR 
=1.03, p=0.002) and adherent (A) (OR 
=1.02, 0.034)  
 
Cairoli (2014) (P) (A)  
Jiann (2006)  
Kim et al (2014)  
Lee et al (2010)  
Salonia (2008b)  







ICI   
 
 Purvis (1999)  








 Kim et al (2014) 
Significantly greater discontinuation for 
middle school graduate or below 
compared to high school graduate or 
above p=0.049. 
OR: 0.48, p= 0.05 
Rubio-Aurioles (2013) 
(P) Significant higher rates of 
persistence for primary, secondary or 
tertiary education in comparison with 
no education) p=0.047 
Cairoli (2014) (P)(A)  
Rubio-Aurioles (2013) (A)  
Postgraduate Vs no formal education 
(P)(A) 
Primary education Vs formal 
education (P)(A) 
Secondary education Vs formal 
education (P)(A) 




Salonia (2008b)  
high education group indicated 
significantly higher rates of persistence 
compared to patients in the low 
education group UVA: OR = 2.46, 
p=0.005 
University education Vs formal 
education (P)(A) 
Salonia (2008b)  
higher level of education not 
significant using MVA 
Employment 
Being in FT 
employment 
PDE5I  Overall work status  
 
El-Meliegy (2013) 
(P): FT employment was related to a 
significantly higher rates of persistence 
p= 0.010   
(P): being employed FT opposed to 
being unemployed was associated with 
significantly higher rates of persistence 
OR: 0.28, p=0.024 
(P): being employed FT as opposed to 
retired was associated with significantly 
higher rates of persistence OR: 0.411, 
p=0.009 
(A): FT employment was related to a 





Unable to work vs. employed/student 
Unemployed/other vs. 
employed/student  
Cairoli (2014) (P) 
FT/PT/retired/unemployed 
El-Meliegy (2013)  
(P) FT as opposed to PT 




(A): being employed FT opposed to PT 
was associated with significantly higher 
rates of adherence OR: 0.59 p=0.007 
(A): being employed FT as opposed to 
retired was associated with significantly 
higher rates of adherence OR: 0.411, p= 
0.010 
Cairoli (2014)  
(A) Being employed FT compared to 
part time, retired, unemployed 









PDE5I    Kim (2014) 
Being of Catholic 
religion 
PDE5I  Kim (2014) 
Continuers 24 (20.7), discontinuers 36 
(9.8), p=0.015 OR: 2.31, p=0.01 








PDE5I  Buvat (2014)  
France vs. Germany 0.045 HR 1.62 
(1.01, 2.59) 
Italy vs. Germany 0.022 HR 0.41 (0.19, 
0.87) 
Greece vs. Germany 0.010 HR 0.32 
(0.13, 0.75) 













Related to Treatment 
Medication 
Ineffective 
PDE5I Bai (2015)# 
Ineffective:  
Tad 1 (3.8) 
Buvat (2013)#  
Hardness of erection:  
Tad OaD: 55 (21.4) 
Buvat (2013)  
Duration of erection 
Tad OaD was related to significantly 
increased persistence compared Sild 
PRN: p=0.035 
Tad PRN was related to significantly 
increased persistence compared Sil 
PRN: p=0.003 
 Buvat (2013)  
Hardness of erection 
Tad OaD vs. Sild PRN 
Tad PRN vs Sil PRN 
Tad OaD vs. Tad PRN 
Duration of erection 
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Tad PRN: 46 (18.3)  
Sild PRN: 55 (21.1) 
Duration of erection 
Tad OaD: 11 (4.3) 
Tad PRN: 7 (12.8)  
Sild PRN: 24 (9.2) 
Buvat (2014)# Total: 35 (4.4) 
Hardness of erection: 33 (4.2) 
Duration of erection: 2 (0.2) 
Carvalheira (2012)# 61 (38.1) 
Carvalheira (2014)#: 23 (15.5) 
Choi (2014)# Total: 14 (15.5) 
Insufficient response: 
Tad OaD: 5 (5.5)  
Tad alternative days: 9 (10)   













El-Galley (2001)# 14 (7)  
Fagelman (2001)# 64 (39)  
Green (1999)# 
Minimal response: 6 (15) 
Incrocci (2003)#: 30 (60) 
Jiann (2006)# 104 (23.9) 
Kim (2015)# Tad 2.5mg; 2 (0.9) 
Lee (2010)# 8 (15) 
Ljunggren (2008)# 3 (2.3) 
McMurray (2007)# Total 52 (7.5) 
Year 1: 22 (2.2) 
Year 2: 19 (2.3) 
Year 3: 14 (1.9) 
Year 4: 7 (1.1) 
Montorsi (2004)# 173 (23.8) 
Panache Navarrete (2017)# 90 (38.8) 
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Raina (2003b)# 5 (10.4) 
Roumeguere (2008)#: 38 (2.4) 
Rubio-Aurioles (2013)#  
Tad:60 (19.0) 
Sild: 17 (15.0) 
Vard:13 (17.0) 
Salonia (2008a)# 28 (54.9) 
ICI Alvarez (1998)# 69 (8.0)  
Armstrong (1994)# 3 (10.0)  
Gerber (1991)# 
Inadequate erectile response 9 (12.5) 
Kunelius (1999)# 9 (13.0) 
Panache Navarrete (2017)# 11 (39.3) 
Perimenis (2001)#3 (7.5) 
Polito (2012)# 33 (12) 
Raina (2003a)# 18 (17.6) 
Rowland (1999) 
Those that reported a lack of efficacy 





Sung (2014)# 111 (37) 
Sexton (1998)#: 16 (18.3) 
US  Mulhall (2001)# 30 (50.8) 
Panache Navarrete (2017)# 14 (28) 
Raina (2005)# 16 (29.6) 
Raina (2007)#: 9 (16.0) 
   
PP Sexton (1998)# 
Malfunction: 2 (4.7) 
   
Side-effects/Fear 
of side-effects 
PDE5I Bai (2015)# 
Adverse event 
Tad 20mg: 3 (0.9) 
Buvat (2014) # Total: 23 (2.9) 
Adverse event; 22 (2.8) 
Un-wanted spontaneous erections 1 (0.1) 
Carvalheira (2014)#:  
Fear of/side effects 15 (10.1) 
Jiann (2006) 
A higher incidence of adverse events in 
continuers than discontinuers 63% and 
47% respectively, p=0.01 
Carvalheira (2012):  
Men who reported side-effects were 
less likely to discontinue treatment OR: 
0.396, p=0.002. 
Buvat (2013) 








Choi (2014)# Total: 5 (4.5) 
Side effects; 
Tad OaD: 3 (2.7)  
Tad alternate days: 2 (1.8)  
Cimen (2009)# 4 (1.3) 
El-Galley (2001)# Total: 10 (8) 
Side-effects: 2 (1.6) 
Worsened Peyronie’s disease: 2 (1.6) 
Un-wanted spontaneous erections  
6 (4.8) 
Fagelman (2001)# Total: 13 (6.9) 
Side-effects: 7 (3.1) 
Peyronie’s disease: 3 (1.9) 
Chest pain: 3 (1.9) 
Incrocci (2003)#: 8 (16) 
Kim (2014)# 19 (3.9) 
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Kim (2015)# Total: 6 (2.8) 
Tad 2.5mg: 3 (1.4) 
Tad 5mg: 3 (1.4) 
Klotz (2005)# 
Adverse (headache and rhinitis) 4 (1.7) 
Lee (2010)# 4 (7.5) 
Li (2016)# Total: 4 (4.6) 
Tad 5mg :  
headache and dyspepsia: 1 (1.15) 
Myalgia: 1 (1.15) 
Tad 20mg: 
Headache/back pain: 1 (1.15) 
Flushing and headache: 1 (1.15) 
Ljunggren (2008)# 3 (2.4) 
McMurray (2007)# Total: 11 (1.3) 
Year 1: 5 (0.5) 
72 
 
Year 2: 2 (0.2) 
Year 3: 1 (0.1) 
Year 4: 3 (0.5) 
Panache Navarrete (2017)# 
Fear of/ADR:13 (6.4) 
Ricardi (2010)# 
Intolerable adverse events: 3 (5.78) 
Headache: 1 (1.9) 
Anaphylactic reaction: 1 (1.9) 
Roumeguere (2008)#: 23 (1.4) 
ICI Armstrong (1994)# 1 (3.0) 
Gerber (1991)#: 
pain due to injection: 12 (16.6) 
Irwin (1994)# 
pain: 2 (3.3) 
Kunelius (1999)#: Total: 7 (10.1) 
Rowland (1999) 
Those that discontinued were more 
likely to report side-effects p=0.038 
 Lehmann (1999) 
Pain from injection 
Aching pain in corpus cavernosum  
New scar tissue 
Bleeding from injection site 
Secondary penile deviation 
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Fibrosis in the penile shaft 3 (4.3%) 
Pain after injection 4 (5.8%) 
Panache Navarrete (2017)# 
Fear of/ADR 9 (20.9) 
Perimenis (2001)# 
Peyronie’s disease:1 (2.5) 
Polito (2012)# 
Injection pain: 23 (8.4) 
Raina (2003a)# 
Priapism: 1 (0.9) 
Sexton (1998)# 
Side-effects: 12 (23)  
Sung (2014)# 
Adverse side-effects: 16 (4.4) 
 
Erection lasting longer than desired 
Priapism 
 
US  Panache Navarrete (2017)#    
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Fear of/ADR 16 (32)  
Raina (2007)# 
urethral pain and/or burning: 4 (7.4) 
Raina (2005)# 
urethral pain and/or burning: 4 (7.4) 
PP Sexton (1998)#: 
Infection or erosion: 4 (9.4) 
   
Medication lacks 
spontaneity 
PDE5I Carvalheira (2012)# 14 (2.6)  
Kim (2014)# 11 (2.2) 
Son (2004)# 2 (1.2)  
   
ICI Sexton (1998)# 14 (16.1) 
Sung (2014)# 43 (14.6) 
   
US  Mulhall (2001)# 20 (34.0)    
Specific to ICI Treatment 
Administration ICI Alvarez (1998) # 
Inability/unwilling to self-inject: 18 (2.0) 




reluctance to use injections/difficulty with 
technique/method regarded as 
unacceptable: 7 (24.0) 
Gerber (1991)#   
did not like injections: 7 (9.7) 
Irwin ( 1994)# Total: 4 (6.65) 
physical limitations: 3 (5) 
needle phobia: 1 (1.65) 
Polito (2012) # 
difficulty, fear, pain when using injections: 
18 (15)   
Raina (2003a)#  Total: 12 (11.8) 
fear of injections: 6 (5.9) 
troublesome procedure: 6 (5.9) 
Rowland (1999)# 
procedural aspects surrounding the 
injection: 10 (8.4) 
The effort to prepare and inject was 




Sexton (1998)# Total: 9 (10.3) 
Fear of needles or injection procedure: 5 
(5.7) 
manual dexterity: 4 (4.6) 
Sung (2014)# 




ICI    
 
 Rowland (1999) 




ICI Purvis (1999)#  
Did not influence the decision to use the 
treatment.  
   
Fully automatic 
RFSU pistol  
ICI Purvis (1999)# 
Did not influence the decision to use the 
treatment. 
   
Manual Injection 




ICI Purvis (1999)# 
Discontinuers: 35.3%, compared to 27.7% 
continuing 
   
77 
 
semi-automatic BD pistol (13.1% compared 
to 23.7% continuing) 
Using papaverine-
phentolamine (15 
mg; 0.5 mg)  
 
ICI Purvis (1999)# 
Continuers 24.3%, discontinuers 14.6% 
(n=766) 
   
Using; 
- Low dose 
Aprostadil (0 ± 10 
mg) 
- High dose 





ICI Purvis (1999)# 
Did not influence the decision to use the 
treatment. 
   
Specific to PDE5I medication 




Having a history 
of ED treatment 
utilization 
PDE5I   Souverein (2002) 
Discontinuation was less frequent 
among patients with a history of ED 
treatment use compared with those 
with no prior history: 28.6% and 43.9% 
respectively. Adjusted RR 0.48 (95% CI: 
0.31 – 0.76). 
Sung (2014) 
Using Tadalafil, 
Sildenafil or  
Vardenafil  
PDE5I   El-Meliegy (2013) 
(P) using Sild at initial prescription 
rather than Vard was associated with 
increased persistence OR: 0.450, 
p=0.023  
(A) using Sild at initial prescription 
rather than Vard was associated with 
increased adherence OR: 0.42, p= 0.015 
Rubio-Aurioles (2013) 
(P) Tad was associated with increased 
persistence when compared to Sild OR: 
1.6 p=0.006.   
(A) Tad was associated with increased 
adherence when compared to Sild OR: 
1.3, p=0.021. 
El-Meliegy (2013)  
(P) Using Tad as opposed to Sild 
(A) Using Tad as opposed to Sild 
Rubio-Aurioles (2013)  
(P) Using Sild as opposed to Vard  




Able to tolerate 
treatment at 1 
month 
PDE5I   Roumeguer (2008) 
Toleration of treatment after 1 month 
(N = 1,350; 98% of total) was associated 
with continued use compared to 
patients who did not well tolerated at 1 
month (N = 31; 2% of total): adjusted 




of trying  dose 
titration  
PDE5I   Jiann (2006) 
Dose titration was associated with 
significantly higher rates of 
continuation p=<0.01 
 
Having a dose 
greater than 
50mg  
PDE5I   Jiann (2006) 
Having doses greater than 50mg was 
associated with significantly higher 
rates of continuation p=<0.01 
Jiann (2006) 
Having a responding dose greater 
than 50mg 
Short window of 
time in which the 
drug is effective 
PDE5I Buvat (2013)#  
Tad OaD: 0 (0.0) 
Tad PRN: 1 (0.4) 
Sild PRN: 11 (4.2) 
Buvat (2013) 
Significantly higher rates of 
continuation for those using; 
-Tad OaD compared to those using Sild 
PRN p=<0.001 
 Buvat (2013) 




- Tad PRN compared to those using Sil 
PRN: p=0.006 
 
Slow onset of 
action 
PDE5I Buvat (2013)#  
Tad OaD: 9 (3.5) 
Tad PRN: 5 (2.0) 
Sild PRN: 10 (3.8) 
Buvat (2014)# 3 (0.4) 
  Buvat (2013) 
Tad OaD vs. Sild PRN 
Tad PRN vs Sil PRN 
Tad OaD vs. Tad PRN 
 
Condition Specific Factors  
Aetiology  PDE5I Psychogenic ED as opposed to organic: 
Rubio-Aurioles (2013)#  
(P) Higher rates of persistence for men with 
ED of psychogenic aetiology  (79 persistent 
patients [23.2%] versus 15 non-persistent 
patients [8.9%]). 
(A) Higher rates of adherence for men with 
ED of psychogenic aetiology (78, [22.6%] of 
adherent patients versus 16 [9.8%] of 
patients who were non-adherent). 
Psychogenic ED as opposed to organic: 
Kim (2014) 
Psychogenic ED:  
The proportion of the patients with 
psychogenic ED in the discontinuation 
group (47.4%) was significantly greater 
than in the continuation group (32.8%) 
(P¼0.004). 
Venogenic ED opposed to Arteriogenic, 
Diabetic and Iatrogenic etiologies:   
 Buvat (2014) 






Compared to venogenic aetiology 
participants with the following 
aetiologies indicated significantly higher 
rates of discontinuation;   
arteriogenic OR = 3.4, P = 0.01 
diabetes OR = 6.9, P = 0.001 
iatrogenic OR = 7.5, P < 0.001. 
ICI    Rowland (1999) 
ED including  an organic component 
Having more 
severe levels of 
ED  
PDE5I   El-Meliegy (2013) 
(P) Having moderate as opposed to 
severe was associated with increased 
persistence 0.017. 
Roumeguer (2008) 
Patients with lower ED severity were 
more likely to continue compared to 
severe ED:  
- normal ED (adjusted OR = 6.88; 95% 
CI: 3.68–12.86; P < 0.0001);  










- mild ED (adjusted OR = 7.83; 95% CI: 
4.25–14.44; P < 0.0001); 
- moderate ED (adjusted OR = 2.06; 95% 
CI: 1.01–4.19; P = 0.05). 
Rubio-Aurioles (2013)  
(P) Moderate as opposed to severe ED 
was associated with higher rates of 
persistence OR: 0.6, p=0.029 
(A) Mild and Moderate as opposed to 
severe ED was associated with higher 
rates of adherence OR: 0.5, p=0.037 
and OR: 0.5, p=0.016 respectively. 
Salonia (2008b) 
Compliant patients indicated a 
significantly greater SHIM score i.e. had 
less severe ED: UVA: p=0.01 / MVA: 
p=0.01. 
Sato (2007) 
Patients with lower ED severity were 
more likely to continue compared to 
severe ED HR: 0.960 CI: 0.931–0.990, 
p=0.025 
El-Meliegy (2013)    
(P) having mild as opposed to severe 
ED 
(A) having mild OR moderate as 
opposed to severe ED 
Rubio-Aurioles (2013)  






A shift of =/> 2 or 




PDE5I   Mazzola (2013)  
Significantly higher rates of 
continuation were reported for those 
with such a score on the EHS, p= <0.001 
 
Shorter duration 
of ED symptoms 
PDE5I  Jiann (2006):  
Those that continued had a shorter 
duration of ED (49.6 ±77.5 months) 
opposed to those that discontinued 
(52.5 ± 50.0), p=<0.05 
Rubio-Aurioles (2013) 
(A) Those that were adherent had a 
shorter duration of ED symptoms (those 
that had ED symptomology for ≥ 4 years 
compared to those that had ED 
symptomology for <1 year) OR: 0.4 
p=0.004 
 
El-Meliegy (2013):  
(A) Those who were adherent had a 
longer duration of ED (31.0 versus 24.0 
years) OR:1.008 
Kim (2014) 
Those that persisted had a longer 
duration of ED (m=5.13±3.87 years, sd) 
compared to those with a shorter 
duration (m=4.22 ± 3.33 years, sd) 
p=0.026. OR: 0.93, p=0.03 
 
Cairoli (2014) (P) (A)  
El-Meliegy (2013) P 
Rubio-Aurioles (2013) 
(P) (A) 1–2 years versus < 1 year 
(P) (A) 2–4 years versus <1 year  
(P) ≥ 4 years versus <1 year 
 
Comorbidities 
Due to the effects 
of co-morbidities  
PDE5I El-Meliegy (2013)# 
Hypertension 
Cairoli (2014)  
Coronary artery disease 
Roumeguer (2008) 
Pelvic surgery 
Treatment was continued by 71% of the 
patients with a history of pelvic surgery 
Buvat (2014)  
Co-morbid conditions 
Cairoli (2014) (P) (A)  
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(P) Higher proportion of persistent patients 
had hypertension (154 [48.1%] versus 68 
[39.3%]) 
(A) A higher proportion of adherent patients 
had hypertension (146 [49.7%] versus 76 
[38.2%]) 
Klotz (2005)#  
tumour/hip prosthesis: 3 (1.3) 
Ljunggren (2008)# 
co-morbid conditions: 1 (0.8) 
Son (2004)#  
co-morbid conditions: 6 (3.9) 
 
those with the condition had higher 
rates of discontinuation p=0.002  
 
(N = 48) vs. 88% of those with no 
history (adjusted OR = 0.40; 95% CI: 
0.18–0.93; P = 0.03). 
Kim (2014)  
BMI 
Those with a BMI of ≥ 23 were more 
likely to continue(273, 85.3%) 
compared to those that discontinued 
(75, 72.1), p=0.002 
Overall participants who had a higher 
BMI (kg/m2; m=24.60 ± 2.38, sd) were 
more likely to continue compared to 
those that discontinued (m=23.99 ± 
2.60, sd) p=0.019. OR: 0.92, p=0.09 
Weight (kg) 
Those who continued had a higher 
weight (m=71.93 ± 8.55, sd) compared 
to those that discontinued 





Kim (2014)  






CACI (Charlson Comorbidity Index) 
score 
 
 ICI Gerber (1991)# 
Developed a significant inter-current illness: 
4 (5.5)  





Sexton (1998)#  
co-morbid conditions: 3 (3.4) 
Cardiovascular disease  
Cerebrovascular attack 
Previous radical pelvic surgery 
including prostatectomy and 
cystectomy 
unilateral or bilateral nerve sparing 
prostatectomy   
Previous pelvic radiotherapy 
PP Sexton (1998)#  
co-morbid conditions: 1 (2.3) 




health  or recent 
injuries or 
operations 
PDE5I Conaglen (2012)# 13 (8.4) 
Roumeguere (2008)# 14 (1.1) 
   
ICI Alvarez (1998)# 36 (4.0) 
Armstrong (1994)# 4 (13.0) 
   
Other medications and treatments 
Due to other 
Medications and 
Treatments 
PDE5I Kim (2014)# 
More important to treat other conditions: 7 
(1.4) 
Souverein (2002)  
Discontinuing was highest among 
patients using:  
Souverein (2002)  
Lipid-lowering drugs 





incontinence materials: 85.7%; adjusted 
RR 2.61, 95% CI: 1.41 – 4.83  
antidepressants: 80.0%; adjusted RR 
3.41, 95% CI: 1.19 – 9.77) 
nitrate therapy 
73.9%, adjusted RR 2.23, 95% CI: 1.30 – 
3.82. 
Insulin 
 adjusted RR 1.71, 95%CI: 1.06 – 
2.93. 
 
Were associated with increased 
continuation; adjusted RR 0.59, 95% CI: 
0.36 – 0.97. 
low dose acetylsalicylic acid 
benign prostatic hyperplasia products 
Other clinical factors 
Type of physician  PDE5I  Buvat (2014) 
Those diagnosed by a GP rather than a 
urologist showed significantly higher 
levels of continuation OR: 0.27 (0.12, 
0.56) p= <0.001 
 



























ICI   Sung (2014) 
More patients were able to achieve 
penile rigidity adequate for sexual 
intercourse in the continuing group 
than in the withdrawal 








ICI  Rowland (1999): 
Higher rates of drop out in those with 
co-existent premature ejaculation: OR: 































Fear of drug 
dependency 
PDE5I Carvalheira (2012)# 10 (3.0)    
Fear that 
medication is 
harmful for the 
heart 
PDE5I Carvalheira (2012)# 25 (7.6) 
Carvalheira (2014)#: 6 (4.0) 
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Averse to taking 
medication 




PDE5I Montorsi (2004)# 94 (12.9)     
Don't want to 
take a pill 
everyday 
PDE5I Buvat (2014)# 12 (1.5) 
 
Buvat (2013) 
-Higher rates of discontinuation for 
those taking Tad OaD compared with 
Sild PRN: p= <0.001 
-Higher rates of discontinuation for 
those taking Tad OaD compared with 
Tad PRN: p=<0.001 
 
 Buvat (2013) 
Tad PRN vs Sild PRN 
 
Prefer a pill every 





-Higher rates of discontinuation for 
those taking Sild PRN compared to Tad 
OaD, p= <0.001 
- Higher rates of discontinuation for 
those taking Tad PRN compared to Tad 
OaD , p=<0.001 
 
 Buvat (2013) 




Not willing for sex 
life to depend on 
medication/medic
ation controls sex 
life 
PDE5I Buvat (2014)# 3 (0.4) 
Kim et al (2014)# 36 (7.4) 
Son et al (2004)# 4 (2.5) 
Buvat (2013) 
Higher rates of discontinuation for 
those taking Sild PRN compared to 
those taking Tad OaD, p= 0.015 
 
 Buvat (2013) 
Tad PRN vs Sil PRN 






PDE5I Carvalheira (2012)# 4 (1.2)  
Jiann (2006)# 71 (16.3) 
   
Forgetting to buy 
or to get medical 
prescription 
PDE5I Carvalheira (2014)#: 3 (2.0)    
Satisfaction with 
treatment 
ICI   Lehmann (1999): 
Continuers were more satisfied with 





ICI Perimenis (2001)# 7 (17.5) 
Polito (2012)# 33 (12) 
   
Would 
recommend 
treatment to a 
friend 
ICI   Lehmann (1999): 
A higher proportion of those who 




treatment to a friend (continuers 65, 





PDE5I Carvalheira (2014)#: 17 (11.4) 
Roumeguere (2008)#:  12 (0.8) 
   
ICI   Lehmann (1999) 





PDE5I Carvalheira (2014)# Total: 25 (16.8) 
To avoid bad performance 15 (10.1) 
To improve performance 
 10 (6.7) 










Having a partner PDE5I   Mazzola (2013)   
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Having a partner was reported as 
significantly Increasing persistence: p= 
<0.01 
Having no partner PDE5I Conaglen (2012)# 4 (2.6) 
Green (1999)#: 5 (12.5) 
Raina (2003b)# 1 (2.0)  
Roumeguere (2008)#: 27 (1.7) 
   
ICI Armstrong (1994)# 4 (13.0) 
Irwin (1994)#: 9 (15) 
Raina (2003a)# 4 (3.9) 
Sexton (1998)#: 10 (11.5) 
   




PDE5I    Cairoli (2014) (P)(A) 
Kim et al (2014) 
Salonia (2008b) 











PDE5I  Buvat (2014) 
associated with an increased risk 





PDE5I    Kim (2014) 
Salonia (2008b) 




PDE5I Carvalheira (2014)#: 13 (8.7)    




PDE5I   Mazzola (2013)  
Having a partner =/>10 years younger 
increased persistence significantly, p= 
<0.01 
Kim et al (2014) 
Partners illness ICI Kunelius (1999)#: 2 (2.9)    
Personal  
For extra marital 
relations 
PDE5I   Carvalheira (2014): 8.1%   
Work 
commitments 
ICI Armstrong (1994)# 1 (3.3)    
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Cost of Treatment 
Cost PDE5I Buvat (2014)# 16 (2.0) 
Carvalheira (2012)# 22 (6.7) 
Carvalheira (2014)#: 8 (5.4) 
Cimen (2009)# 51 (16.5) 
Conaglen (2012)# 18 (11.6) 
Fagelman (2001)# 5 (0.6) 
Green (1999)#: 2 (5) 
Incrocci (2003)#: 12 (24) 
Jiann (2006)# 93 (21.4) 
Kim (2014)# 31 (6.4) 
Klotz (2005)# 9 (3.8) 
Lee (2010)# 24 (45.3) 
Ljunggren (2008)# 1 (0.8) 
Panache Naverette (2017)# 20 (8.62) 
Roumeguere (2008)# 34 (2.2) 
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Son (2004)# 2 (1.2) 
 ICI Sung (2014)# 13 (4.4)  
Gerber (1991)#: 4 (5.5) 
Sexton (1998)#: 4 (4.6) 
   
US  Mulhall (2001)# 14 (25.4)    




PDE5I Carvalheira (2012)# 8 (2.4) 
Cimen (2009)# 18 (5.8) 
Fagelman (2001)# 1 (0.6) 
Jiann (2006)# 75 (17.3) 
Klotz et al (2005)#  
Lack of opportunity or desire 33 (14.1) 
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Kim (2014)# 9 (1.8) 
Ljunggren (2008)# 1 (0.8) 
Salonia (2008a)# 1 (1.9) 
Son et al (2004)# 2 (1.2) 
ICI Irwin (1994)# 18 (30) 
Sung (2014)# 16 (5.4) 
Gerber (1991)# 5 (6.9)  
Sexton (1998)# 6 (6.9)  
   
US  Raina (2007)#:5 (8.9)    
PP Sexton (1998)# 3 (6.9)    
Partner lack of 
interest in sexual 
relationship 
PDE5I 
Carvalheira (2014)#: 9 (6.0) *Lack of 
emotional and physical stimulus by the 
partner increased utilisation of treatment. 
Jiann (2006)# 36 (8.2) 
Kim (2014)# 6 (1.2) 
Klotz (2005)# 19 (8.1) 
Salonia (2008a)# 5 (9.8) 
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Kim (2014)# 15 (13.1) 
Son (2004)# Total: 20 (12.8) 
Of partner: 12 (7.7) 
Of patient: 8 (5.1) 
 
   
Partners level of 
sexual activity 
PDE5I    Carvalheira (2012) 
Conflicts within 
one’s relationship  
PDE5I 
Carvalheira (2014)#: 5 (3.3) 
Conaglen (2012)# 9 (5.8) 
El-Galley (2001)# 2 (2.4) 
   
ICI Sung (2014)# 3 (1.0)    
Low satisfaction 
with sex life 
ICI  
Rowland (1999): 
Higher rates of drop out associated with 
a lower level of satisfaction with one's 
current sexual life OR: 1.24, p= 0.054  
  
Better quality of 
sexual 
relationship ICI  
 Lehmann (1999): 
Continuers 63 (91.0) reported better 
quality of sexual relationship than 




Person within the 









PDE5I Buvat (2014)# 5 (0.6) 
Carvalheira (2014)#: 5 (3.3) 
Roumeguere (2008)#: 12 (0.8) 
  Buvat (2013) 
Tad OaD 
Sild PRN 
Tad PRN  
 






ICI   Lehmann (1999): 
Those that persisted were more 
significantly more satisfied with 
treatment p=0.02 
 
Partner aware of 
and involved in 




 Carvalheira (2012): 
Continuers were less likely to 
discontinue compared with men whose 
partner was not involved in the 












Length of time 
before seeking 
help for ED 
PDE5I    Salonia (2008b) 
Personal behavior 
Lower frequency 
of masturbation  
ICI  Rowland (1999): 
Higher rates of drop out indicated for 
those with a lower frequency. OR: 1.35, 
p=0.027 
  




PDE5I Carvalheira (2012)# 18 (5.5) 
Carvalheira (2014)#: 3 (2.0) 
Panache Naverette (2017)# 17 (7.3) 
 
   
ICI Panache Naverette (2017)# 3 (6.9%)    
US Panache Naverette (2017)# 2 (4%)    
Pre-treatment 
sexual activity ( 









=/>4 times per 
month) 
Pretreatment sexual activity increased 
persistence significantly, p= <0.001 
Greater No of 
sexual attempts in 
the first month of 
treatment 
PDE5I   Roumeguere (2008): 
Patients with a greater number of 
sexual attempts in the first month were 
significantly more likely to continue the 
treatment at 12 months (adjusted OR = 
1.09; 95% CI: 1.03–1.16; P = 0.003). 
 
Life style 
Level of exercise PDE5I    Kim (2014) 
